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Abstract 
 
Introduction: When used at the recommended and approved therapeutic dose, 
paracetamol is effective. Paracetamol is available in various forms and easily 
accessible from general dealers and pharmacies. The liquid form is the preferred 
form given with a device to children. Hypothesis: Paracetamol is effective within a 
defined therapeutic range; however, are prescribers and caregivers using 
paracetamol as authorised by regulators? Method: A qualitative review of product 
specific labelling and the department of health recommendations was conducted and 
evaluated by means of arithmetic means differences to the regulator requirements. 
Surveys of healthcare professionals and caregivers determined the quantity 
administered and to establish if a device was used. Results: The dosing information 
from product specific labelling, the department of health and the regulator source 
were reviewed for recommended dose, frequency of administration, maximum daily 
dose and recommendations for overdose treatment. There are similarities and 
differences with the null hypothesis being proven. Conclusions:  Product labelling and 
department of health recommendations do not conform to the regulator accepted 
therapeutic dose. There was no unambiguous legislative medicine guideline on the 
age of a child with children between six and twelve being underdosed with liquid 
paracetamol in terms of volume and strength. 
 
Keywords: paracetamol, therapeutic dose, children, labelling requirements. 
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Disclaimers 
 
Terminology Drug and medicine 
The preferred terminology for a drug is medicine by the South African regulator. 
Every effort has been made to use the international standard of drug in this research 
project. 
 
Product Reference Source 
Monthly Index of Medical Specialities (MIMS) May 2012 was used as the initial 
source to determine paracetamol mono-component products available on the market. 
A verification was performed against MIMS August 2013. This reference was 
accessible to the researcher and author of this research project and based on 
experience that not many companies invest in the registration of a mono-component 
paracetamol preparation. 
 
MCC Reference source 
The Medicines Control Council referred to the accepted standard references as 
Goodman and Gilman and the Martindale. Theses references are The 
Pharmacological Basis of Therapeutics and The Complete Drug Reference 
respectively. 
 
Records 
1) Individual completed surveys will be retained until the research project has been 
finalised and data cannot be used without the permission of the respondents. 
2) Photographic observations were used to record the experiment of medical 
devices. They were not included in the appendix due to file size limitation and are 
available upon request. 
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3) Product information labelling is available upon request and not included due to file 
size 
4) Agency guideline has not been included as appendices. These have been 
reflected in the reference list. Should a copy be required, they can be supplied 
electronically. 
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1. Introduction 
 
Paracetamol ( South Africa. Medicines and Related Substances Act 101, Schedules) 
is approved by regulatory authorities as a medicine ( South Africa. Medicines and 
Related Substances Act 101, S1, medicine) for the treatment of pain and fever in 
children and adults (South Africa. Medicines and Related Substances Act 101, 
schedules and Bertolini et al, 2006) but yet its exact mechanism of action is unknown 
(Bertolini et al, 2006). 
 
Paracetamol only containing products are available in a variety of pharmaceutical 
dosage forms (MIMS 2012) and can be purchased by a consumer from a general 
dealer store or from pharmacy or can be administered in hospital ( South Africa. 
Medicines and Related Substances Act 101, Schedules), in South Africa. It is one of 
two substances that are available without prescription, the other being aspirin (South 
Africa. Medicines and Related Substances Act 101, Schedules). 
 
Orally administered dosage forms are capsules, tablets or syrups (solutions) (MIMS, 
May 2012).The quantity of paracetamol is either 500 mg for the capsule and tablet 
(conventional, effervescent or meltab) or 125 mg meltab. Paracetamol syrup forms 
are available as 60 mg per 0,6 ml or 120 mg per 5 ml. 
Rectal preparations contain either 125 mg or 250 mg of paracetamol per suppository 
(MIMS, May 2012). 
Paracetamol injection contain either 1 g per 100 ml (100 ml vial) or 10 mg per 1 ml 
(50 ml vial) which are administered in hospital (MIMS, May 2012). 
 
The different pharmaceutical dosage forms with different quantities of paracetamol 
could result in an over use of paracetamol leading to toxicity with severe liver 
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damage (Bradfield (ed), Paracetamol 2013). Although paracetamol is reported to 
have few side effects which are usually tolerated by the user, ovedosage  can be 
common because of the narrow margin between therapeutic dose and toxic dose 
(South Africa. Department of Health, Essential Medicines List, 2008). 
 
Orally administered paracetamol is less irritant on the gastrointestinal tract (Bertolini, 
2006)) when compared to other non-steroidal anti-inflammatory agents and was 
therefore used as first line treatment especially in children (Bradfield (ed), 
Paracetamol 2013). 
 
The focus of this research was to evaluate whether paracetamol was administered to 
children at therapeutic doses by caregivers. This involved reviews of various pieces 
of South African legislation and comparing them with international legislation, the 
review of packaging information of South African products and determination if 
medical devices were used to give paracetamol to children.  
 
The Children’s Act (South Africa. Department of Social Development, Act 38 of 2005) 
defines the legal age for a child as an individual under the age of 18 years while the 
Medicines and Related Substances Act (Act 101 of 1965) did not provide age clarity 
on age breakdown for dose administration. 
 
The reason for the emphasis on children was concern of protecting children as they 
are vulnerable especially when administered medication by their caregivers. 
Furthermore, the revised dosing for liquid preparations by the United Kingdom’s 
Medicines and Healthcare Products Regulatory Authority in 2011 (United Kingdom, 
Medicines and Healthcare Products Regulatory Authority, 2011) had highlighted the 
need to be vigilant (Jones, 2012)) when medication is given to children especially 
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when these medicines were easily accessible to the public via general dealers (South 
Africa. Medicines and Related Substances Act 101, section 22A). Unless published 
in public media, neither the general dealer nor the consumer would be aware of 
legislation changes which could affect the manner in which they sale or use 
paracetamol medication as legislative changes are only published in government 
gazettes in South Africa. 
 
 
 
 
 
 Page 15 of 82 
2. Literature Review 
 
2.1 Introduction 
Paracetamol is widely used internationally for the treatment of pain and fever in all 
age groups with recent focus on the intravenous dosage form (Gazarain, Drew and 
Bennett, 2014) and its associated overdose as a result of administration errors. 
Consequently  recent research focussed on the treatment of paracetamol overdose 
and not its efficacy . Paracetamol is used on its own or combined with other active 
ingredients. 
 
As paracetamol preparations are widely available to the public via general dealers or 
could either be recommended or prescribed by healthcare professionals, a review of 
the available paracetamol containing preparations literature and standard treatment 
guidelines should support the South African regulator approved recommended 
therapeutic doses for children. 
 
South African national legislation provided a starting point (South Africa. Medicines 
and Related Substances Act 101) with the review extending to international 
legislation in the United Kingdom and the United States of America. 
 
2.2 Legislative control of medicines 
The principal legislation for governing medicines, or drugs, is the Medicines and 
Related Substances Control Act, Act 101 of 1965, with the short title being the 
Medicines and Related Substances Act ,1965. The national health regulator authority 
in South Africa is known as the Medicines Control Council (MCC). 
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The Medicines and Related Substances Act (South Africa. Medicines and Related 
Substances Act, 1965) provides for the registration, or authorisation, of drugs 
including the assessment of quality, safety and efficacy of drugs, how the drug could 
be sold and to whom it could be sold and where it could be sold.  
 
The drug is further classified according to its pharmacological action, where 
paracetamol as a single component falls under the category antipyretics or 
antipyretics and anti-inflammatory analgesics (South Africa. Medicines and Related 
Substances Act 101, regulation 25). 
 
In terms of safely and efficacy, a medicines must reflect details informing all 
stakeholders of the benefits or commonly referred to as indications, and the risks or 
adverse effects associated with the use of a drug. Information structure for the 
healthcare professional is defined under regulations 8 and 9 (South Africa. Medicines 
and Related Substances Act 101) and expanded under the regulator issued 
guidelines package inserts for human use and package inserts for human medicines 
standardised texts (South Africa. Medicines Control Council, 2014). Similarly, product 
information for the consumer is defined under regulations 8 and 10 and expanded in 
the guideline patient information leaflets (PILs) (South Africa. Medicines Control 
Council, 2014). 
 
The National Health Act 2003 (South Africa. National Health Act 61, 2003) is the 
primary act relating to healthcare providers and health services delivery in South 
Africa. The national department of health had published a consolidated medicine list 
in February 2014 which confirmed that paracetamol is used across all levels of health 
care delivery (South Africa. Department of Health, essential medicines program, 
2014). 
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The National Health Act 61 provides for the establishment of national guidelines 
addressing health care needs in ZA. 
 
2.3 Legislated paracetamol effective dose 
2.3.1 Paracetamol therapeutic dose 
It is the responsibility of the applicant or marketing authorisation holder to provide 
supportive evidence to establish the safe and effective dose for any ingredient to the 
South African regulator, the MCC, before the product could be authorised for sale 
(South Africa. Medicines and Related Substances Act 101, section 15). 
 
With paracetamol, the MCC had made a ruling whereby paracetamol safety was of 
primary concern and hence the MCC applied certain pack size restrictions based on 
paracetamol strengths in preparations in line with international trends (South Africa. 
Medicines and Related Substance Act 101, Schedules). 
 
Legislation (South Africa. Medicines and Related Substances Act 101, Schedules) 
refers to formulations containing paracetamol as a single drug (or mono-component 
products) in strengths of 500 mg in tablets or capsules, 1 000 mg in individually 
wrapped powders or sachets in pack sizes not exceeding 12,5 grams. For liquids the 
prescribed paracetamol content should be 120 mg per 5 ml syrup or less with a 
maximum pack size of 100 ml. Other pharmaceutical dosage forms are 
suppositories, modified release formulations, and injections (South Africa. Medicines 
and Related Substances Act 101, Schedules). 
 
The regulator standard accepted references (South Africa. Medicines Control 
Council, 2014), namely, the Goodman and Gilman and the Martindale, were 
reviewed to obtain paracetamol’s accepted therapeutic dose. 
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There was no documented evidence that paracetamol is not effective for the 
treatment of pain and fever within the defined therapeutic range when used as first 
line treatment for pain and fever. 
 
2.3.2 Paracetamol overdose 
Overdose with paracetamol has been defined as a medical emergency (Heard, 2008) 
internationally including South Africa (Rossiter, 2012). Appendix 8 reflects a list of 
products that were available in South Africa. 
Treatment of paracetamol overdose (or poisoning), especially due to the potential of 
liver failure, requires that the healthcare professional be cognisant of the narrow 
therapeutic index of paracetamol and the treatment regimen for overdose. 
 
Package inserts for human medicines standardised texts (South Africa, Medicines 
Control Council, standardised text, 2010) reflected that overdose in a child as an 
acute ingestion of 140 mg/kg within 4 hours. Treatment was emesis or lavage and a 
single dose of 50 g activated charcoal. Then followed up with N-acetylcysteine (NAC) 
within the first eight to thirty six hours. The recommended NAC intravenous dose was 
firstly 150 mg/kg in 200 ml of dextrose injection administered over 15 minutes, 
secondly 50 mg/kg in 500 ml dextrose injection over 4 hours, and lastly 100 mg/kg in 
1 000 ml of  dextrose injection over 16 hours. “The volume of intravenous fluid should 
be modified for children” (South Africa. Medicines Control Council, standardised text, 
2010) is the only specific reference to overdose treatment in children. 
 
NAC oral treatment was not recommended as first line overdose treatment; however, 
when used, the loading dose was 140 mg/kg dissolved in water followed by 70 mg/kg 
every 4 hours for 17 doses (or three days).  
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This treatment period coincided with the recommendation that patients be monitored 
for at least ninety six hours. 
 
2.4 Medical device 
Simultaneously with the review of effective therapeutic dose was the review of the 
use of an appropriate medical device to administer paracetamol oral liquid 
preparations. This was to determine if current legislation or practice addressed the 
safe use, or administration, of paracetamol preparations to children. 
 
2.5 Paracetamol preparations 
The Medicines and Related Substances Act 101 (South Africa. Medicines and 
Related Substance Act 101, Schedules), indicated that paracetamol was available as 
over the counter medicines directly to the consumer as schedule 0 at a specific 
strength in tablets, capsules, powders or sachets and syrup in limited pack sizes, 
while larger pack sizes were available from pharmacies as schedule 1 products. 
Rectal preparations and modified release formulations were available at pharmacies 
as schedule 2 preparations and could be supplied without a prescription, or as 
pharmacist initiated therapy; while, the injection form was only available via 
prescription as schedule 3 (South Africa. Medicines and Related Substances Act 
101, Schedules). 
The schedule determined to whom and how a medicines could be sold (South Africa. 
Medicines and Related Substances Act, Section 22A). 
 
A review was conducted of marketed products available on the South African market 
(MIMS, May 2012) as consolidated in Appendix 7. 
 
 
 
 
 
 Page 20 of 82 
2.6 Marketing and advertising of drugs 
The private healthcare sector had agreed that they would abide by rules to be self 
regulated (South Africa, Marketing Code Authority, 2013). This was either in terms of 
the Advertising Standards Authority code (South Africa. Advertising Standards 
Authority, 2014) for OTC medicines marketed directly to the consumers or the 
Marketing Codes Authority for prescribed drugs or those advertised to pharmacists, 
holders of a dispensing licence or prescribers . 
The Medicines and Related Substances Act 101, under regulation 45 (South Africa. 
Medicines and Related Substances Act 101, Advertising of medicines), depicted that 
all drugs classified as schedule 0 and 1 can be advertised to the public whilst drugs 
classified as schedule 2 to 6 can be advertised to the healthcare professional only. 
Section 22A of the Medicines and Related Substances Act 1965 (South Africa. 
Medicines and Related Substances Act 101, Control of medicines and schedule 
substances) indicated that Schedule 0 drugs can be sold in an open shop or by a 
general dealer whereas schedule 1 to 6 medicines can be sold in pharmacy or by 
designated healthcare professionals within their scope of practice. 
 
2.7 Clarification of child and administration of medicines 
Children are dependent on guidance from adults in all respects. It is important that 
there is no ambiguity into the firstly the definition of a child and secondly the 
obligations and roles of caregivers and healthcare professionals in the effective 
administration of medicines as per the principles of clinical ethics (Ashcroft, 2007 and 
International Conference on Harmonisation.  Guidelines for Good Clinical Practice, 
1996). 
 
The metabolism of paracetamol is different in children to that of adults (United 
Kingdom. Medicines and Healthcare Products Regulatory Authority, Public 
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assessment report, 2011). Coupled with the narrow therapeutic index of paracetamol 
(Brayfield, Paracetamol, 2014), it is important that the effect therapeutic dose be 
administered to children. 
 
The alcohol content of orally administered preparations reflecting various children 
age groups (South Africa. Medicines Control Council, Alcohol content of medicines, 
2003) must be taken into consideration when paracetamol liquid preparations are 
given to children. This information must be reflected on the labelling (South Africa. 
Medicines and Related Substances Act 101, regulations 8, 9 and 10). 
 
As detailed in the MHRA Public Assessment report (United Kingdom. Medicines 
Regulatory and Healthcare Products Regulatory Authority, Public Assessment 
Report, Liquid Paracetamol, 2011), the route of metabolism is sulphation in children 
and glucoronidation in adults. Further the drug clearance is considered to be lower in 
children than adults with factors such as body weight and rate of metabolism 
influencing the metabolism. 
 
Paracetamol has the highest reported overdose prevalence specifically in children 
under the age of 13 in South Africa (Veale, Wium and Müller, 2013); which 
corresponded to the increase of overdose reports in Australia (Gazarain, Drew and 
Bennett, 2014) as a result of the availability of the intravenous form of paracetamol. 
The common recorded paracetamol overdose symptoms are pallor, nausea, 
vomiting, anorexia and possibly abdominal pain. (South Africa. Medicines Control 
Council, Standardised text, 2010). Mild symptoms has the potential to mask the 
seriousness of liver damage (South Africa. Medicines Control Council, Standardised 
text, 2010). 
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2.8 Hypothesis 
The aim of the research project was to determine whether the authorised therapeutic 
dose of paracetamol preparations that were available on the South African market 
conformed to legislation. Furthermore, to determine if the South African authorised 
therapeutic dose correlated to internationally approved therapeutic doses in children. 
 
The objective was to determine if South African preparations were in agreement with 
the therapeutic dose for children and to determine if South African legislation, private 
sector and public sector, was in line with international recommendations by 
established regulatory health authorities. 
 
The sources for review on paracetamol focussed on governmental policy for 
administration to children. No published references were freely available to indicate if 
prior research focussed on the evaluation of the accepted therapeutic dose of 
paracetamol used in children in South Africa. Recent international publications had 
centred on the determination of mechanism of action and treatment of overdose of 
paracetamol but not comparison of the therapeutic dose (Gazarain, Drew and 
Bennett, 2014). Some international data was available to review the restriction of 
packs sizes (United Kingdom. Medicines and Healthcare Products Regulatory 
Authority; and, the United States of America. Food and Drugs Administration). 
 
The main intent of the research was to determine if paracetamol was being 
prescribed and used at the correct therapeutic dose in the children population in 
South Africa. 
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Paracetamol is effective within a defined therapeutic range; however, are prescribers 
and caregivers using paracetamol as authorised by regulators is the hypothesis of 
this research project. 
 
For the testing of the hypothesis, the dependent variable was South African 
legislation based on international practice compared to the actual use or prescribing 
information appearing on the South African product specific labelling as the 
independent variable. 
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3. Methodology 
 
The mixed methods approach was used to collect information for analysis on 
paracetamol mono-component products. 
The rationale for the focus on mono-component products was ease of availability of 
paracetamol from either a general dealer or pharmacy. Analgesic and antipyretic 
preparations could be single or multiple active component products (MIMS, May 
2012).  
Paracetamol combination products generally contain either other analgesics such as 
aspirin, antihistamines such as diphenhydramine or other active components placing 
them in schedule 2 or higher schedules (South Africa. Medicines and Related 
Substances Act 101, Schedules), and therefore, only available from pharmacies as 
pharmacist initiated therapy or on prescription. 
 
3.1 Legislation overview of effective dosing, medical devices and children 
Legislation directs the control and sale of drugs for therapeutic purposes. 
Paracetamol specific legislative requirements were reviewed in this research project 
to capture the accepted therapeutic dose in South Africa and that recommended by 
other established international regulatory authorities. This section was a qualitative 
analysis based on recordings and observations. 
 
In general, the legislative requirements were comprehensive for medicines which 
focussed not only on quality, safety and efficacy in respect of dosing; but addressed 
marketing and advertising for the safe use of drugs.  
The merit of this method of data collection was the extensive availability of data via 
the internet with the challenge being in the interpretation of information based on 
South African national legislation. 
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3.1.1 Therapeutic dose 
A survey was conducted of current legislative requirements relating to paracetamol 
preparations in South Africa and those as recommended internationally via 
qualitative analysis. Details were recorded on a spreadsheet to consolidate the data 
gathered. 
 
MCC’s accepted references were compared to international recommended 
therapeutic doses to determine if the ZA authorised recommended doses were in line 
with international recommendations. 
 
The merit was that paracetamol is regarded as a safe drug when used within the 
recommended “therapeutic dose with few side effects” (Cranswick and Coglan, 
2000). 
 
3.1.2 Medical Device 
A method was devised (appendix 9) and observations (appendix 12) recorded to 
capture the volume determination of the various medical devices that are available. 
These observations were to determine if marketed oral paracetamol liquid 
preparations contained a medical device to ensure accurate dosing by administration 
of the correct volume or medicine measure. The observations were carried out at 
general dealers stores, a corporate pharmacy group and independently owned 
pharmacies. 
 
The next step was to determine by experimentation and recording of results to 
establish if the available medical devices of medicine measures, syringes and 
household items provided an accurate dose measure as indicated on the product 
labelling or package insert. The experiment was conducted using only one liquid form 
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to ensure consistency of product characteristics thus minimising differences in 
formulation between products. Four different volumes of 2,5 ml, 5 ml, 7,5 ml and 10 
ml were measured based on the medical device calibration and volume limitation. 
 
Solid dosage forms did not require a medical device as administration is orally with a 
liquid preferably water. 
 
Medical devices were not required for rectal preparations as suppositories are 
inserted into the anus by caregivers. 
 
Injections are not for self administration but rather administered by healthcare 
professionals in a clinical setting. In this research project it was assumed that the 
syringe was appropriately marked and calibrated to allow for the correct volume to be 
extracted for administration. 
 
The challenge was establishing a device that would be used as the calibrated 
equipment to verify volume delivery readings when compared to other medical 
devices as the research was not conducted at a university, laboratory or 
pharmaceutical company. However, this was overcome by comparison of a reading 
from one device to another. Visuals were recorded for verification purposes. 
 
3.1.3. Children 
The definition from a South African perspective and that used internationally were 
reviewed to determine if there is consistency in age groups categories. 
The hurdle was determining which specific South African legislation would provide an 
unambiguous “child” definition as the Medicines and Related Substances Act 1965 
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(South Africa. Medicines and Related Substances Act 101) does not contain a 
definition for a child or children.  
The merit was gaining familiarity with other legislation that impact on health decisions 
but which are not frequently encountered and thus not referenced in daily practice. 
 
3.1.4 Public sector guidelines 
The different documentation issued by the South African department of Health was 
reviewed to correlate government policy to ensure that information was consistent 
across treatment guidelines. Furthermore, a comparative analysis was performed to 
determine if the South African government documents had been updated with 
international recommendations including the World Health Organisation 
recommendations. 
The weakness was that information and decisions made by government were not 
effectively or efficiently communicated to all healthcare stakeholders. As an example, 
the pharmaceutical healthcare sector is not made aware of revision via its statutory 
body the South African Pharmacy Council. The information is rather disseminated via 
interested groups or via professional associations or gained from personal review of 
documentation. The Standard Treatment Guidelines and essential medicines list for 
South Africa, Hospital level Paediatrics 2013 is an example of a document (South 
Africa. Department of Health, Standard treatment Guidelines and essential 
medicines List for South Africa, Hospital level Paediatrics, 2013). 
3.2 Paracetamol preparation overview 
A survey was conducted of products available via the private market and via the 
public sector documentation. Sources used were the Monthly Index of Medical 
Specialities (MIMS, May 2012 and MIMS August 2013) and online access to the 
Generics Dictionary (South Africa. Generics Dictionary) and government of health 
pricing and tender documents (South Africa. Department of Health). Verification of 
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information recorded was made comparing data sourced directly from International 
Marketing Survey Health (IMS) for the private sector. 
 
Details recorded and summarised focussed on an overview of dosing and overdose 
captured on the product labelling reflected on the package insert. The package 
inserts were sourced from either purchasing the product, approaching a pharmacy, 
the internet via the South African package insert website (Intekom) or via specific 
company website, if available. 
 
The results from the product labelling review were coded. Code 0 was not meeting 
the South African legislative requirements and Code 1 meant that the product 
labelling met legislative requirements. 
 
Statistical analysis was then performed to determine arithmetic means and reflected 
as a percentage compared to the product total evaluated. 
 
The challenge was determining the starting point for sourcing product labelling 
information. Reliability of the most recent information was based on procurement of 
products from pharmacy or general dealer as products must be sold that are still 
within the manufacturer’s recommended shelf life. Established resources accessed 
via the internet were used to confirm product availability. 
The positive step was cognisance of the reliability of source information. 
3.3 Restriction of sale 
Marketing and advertising were confined to observation of pack size availability at 
general dealers. No observations were noted as there were no contraventions noted 
at the general dealer stores.  
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Observations were not conducted in pharmacy as there are no pack size restrictions 
for paracetamol mono-component products sold in a pharmacy. 
 
3.4 Surveys 
Quantitative data was generated by conducting surveys in the private sector. Sample 
size of five pharmacists and ten caregivers were determined to obtain an overview of 
practice within the time limitation of the research project. Ethics approval was granted 
at the end of February 2014 by the Ethics Committee of the University of the Western 
Cape. 
 
Sampling of pharmacies were chosen at random with the intent to survey pharmacies 
located within different social settings. Data was generated and collected by the 
researcher conducting face-to-face surveys at four independently owned pharmacies 
and one corporate pharmacy. Two of the pharmacies serviced low income groups, 
two were based in middle income areas and the corporate pharmacy was in a 
shopping centre. 
 
The survey design was based on semi-structured interviews to obtain specific 
information with consideration of the respondent’s available time and the opportunity 
for further discussion where acceptable by the respondent. The intent of an audio 
recording was not realised as the audio device malfunctioned prior to survey 
initiation. The survey of both the pharmacist, and healthcare professional, and the 
caregiver were conducted in the five pharmacies. 
 
The design of the survey for the professional was aimed at investigating the 
prescribing data including the availability of a medical device; while the survey of the 
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caregiver was to investigate the appropriate use, administration of paracetamol and 
to ascertain if a medical device was used.  
 
The limitation of the surveys were that most general dealer outlet stores are of 
corporate origin that required approval from head office for activity that is not initiated 
by head office. Due to the research project time constraint, these general dealer 
stores were not approached.  
 
Small community based general dealers were not included as they could purchase 
the originator product in tablet form either in dispensers (42 x 2 tablets) or display 
cards (48 x 2 tablets). The consumer would only purchase on demand for once-off 
use thus there was minimal risk of a child being given more than the therapeutic 
dose. 
 
Face validity confirmed data reliability as the researcher conducted the surveys at the 
pharmacy. Participant Information leaflets including a copy of a blank consent form 
was handed to each possible respondent upon introduction. In addition, the 
respondents were requested to sign the consent form after completion of the survey. 
 
Survey results were analysed quantitatively, Completed surveys records were treated 
anonymously and available for review solely for the purposes of verification toward 
the attainment of the degree. 
 
The merit of direct interaction with the consumer and professionals was that it 
provided an opportunity to initiate discussions about paracetamol. 
The challenges were finding the time and identify pharmacists that would be open to 
participate in the survey within their pharmacies. The advantage of conducting the 
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survey in pharmacy only was that the purpose of the survey was received well by 
respondents willing to participate and not withdrawing their participation and 
responses were addressed in an open manner by the respondents to share their 
knowledge and information with the researcher.. 
 
3.5 Testing of hypothesis 
Data collection was designed to test if paracetamol products on the market conform 
to legislative requirements by determining the number of products meeting the 
legislative requirements, those addressing specific dosing in all children age groups 
and  whether data on overdose has been updated on product labelling. 
The merit of selecting paracetamol was the ease of access to paracetamol 
preparations.  
The challenge was determining if paracetamol was used within the prescribed 
therapeutic dose. 
 
Thus the null hypothesis is that paracetamol is not used or prescribed within the 
therapeutic dose range in ZA. 
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4. Findings and Analysis 
 
4.1 Legislation 
The review of the Medicines and Related Substances Act 101 (South Africa. 
Medicines and Related Substances Act 101) focussed on the regulation of 
paracetamol and its restrictions, the use of medicines in children and labelling 
requirements. Legislative and the effective dose for paracetamol were evaluated 
concurrently.  
 
4.2 Effective dose 
4.2.1 Therapeutic effective dose: South Africa 
The approved therapeutic dose for paracetamol ranges from 30 mg/kg to 1 g per 
single dose with no more than 4 doses per day or within a 24 hour period for children 
from 1 month to adults for oral, rectal and injection administration as captured below 
in tables 1 to 3 respectively. 
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Table 1: Paracetamol ORAL therapeutic dose 
A summary of the recommended single oral dose, the frequency of administration 
and maximum daily dose for different age groups from MCC accepted sources. 
 
Age group Dose(mg) Freque
ncy 
(hours) 
Maximum daily dose MCC Source 
Not defined 325–650 
mg  
4-6 4 g 
2 g (alcoholics) 
Goodman & 
Gilman 
“Usual” - assumption 
adult was implied 
500-1000 4-6 4 g Martindale 
Children: UK licensed dose 4-6 4 doses 
12-16 years 480-750 
10-12 years 480-500  
8-10 years 360-375  
6-8 years 240-250  
4-6 years 240  
2-4 years 180  
6-24 months 120  
3-6 months 60  
1-3 months 30-60  8, if 
necess
ary 
none BNFC 
Neonates >32 weeks 20 mg/kg, 
then 
10-15 
mg/kg 
6-8 60 mg/kg daily 
Neonates 28-32 weeks 20 mg/kg, 
then 
10-15 
mg/kg  
8-12 30 mg/kg daily 
 
 
 
 
 Page 34 of 82 
Table 2: Paracetamol RECTAL therapeutic dose 
A summary of the recommended single rectal dose, the frequency of administration 
and maximum daily dose for different age groups from MCC accepted sources. 
 
Age group Dose(mg)  Frequenc
y (hours) 
Maximum daily 
dose 
(times daily) 
MCC Source 
Not defined 500-1000 4-6 4 Martindale 
5-12 years 250-500  4-6 4 
1-5 years 125-250  4-6 4 
3-12 months 60-125  4-6 4 
1-3 months 30-60 8 None specified BNFC 
Neonates >32 weeks 30 mg/kg, then 
20 mg/kg  
8 60 mg/kg 
Neonates 28-32 
weeks 
20 mg/kg, then 
15 mg/kg 
12 30 mg/kg 
 
Table 3: Paracetamol INTRAVENOUS therapeutic dose 
A summary of the recommended single dose administered intravenously, the 
frequency of administration and maximum daily dose for different age groups from 
MCC accepted sources. 
 
Age group Dose  Frequency 
(hours or 
more 
Maximum daily 
dose 
MCC Source 
Over 50 kg 1 g  4 4 g  Martindale 
 • Between 33-50 kg 
• Chronic 
alcoholism/malnutri-
tion, dehydration 
15 mg/kg 4 3 g (60 mg/kg) 
Children over 50 kg Adult 
dose: 1g  
4 4 g  
Children 33- 50 kg 15 mg/kg  4 3 g (60 mg/kg) 
Children 10- 33 kg 15 mg/kg  4 2 g (60 mg/kg) 
Full term neonates and 
children <10 kg 
7,5 mg/kg  4 30 mg/kg  
10 mg/kg  4-6 30 mg/kg  BNFC 
Premature neonates 
(>32 weeks 
postmenstrual age) 
7,5 mg/kg  8 25 mg/kg  
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The treatment of post immunisation pyrexia is an indication listed in the MCC 
accepted reference source of Martindale (Brayfield (ed.), Paracetamol, 2014); 
however this is not included in any of the package inserts in South Africa and  is 
therefore considered an “off label” claim or use of paracetamol. 
 
The only requirement specified by the MCC for dosage is that the wording “DO NOT 
EXCEED THE RECOMMENDED DOSE” should be reflected in bold (South Africa. 
Medicines Control Council, Standardised text, 2010) on the package insert. Other 
specific wording was “CONTAINS PARACETAMOL – READ THE PACKAGE 
INSERT” on the OTC pack (South Africa. Medicines and Related Substances Act 
101, Schedules ) with the said legislation ambiguous on compulsory wording on other 
pack sizes sold in pharmacy or dispensed by an authorised prescriber. 
 
4.2.2 Effective therapeutic dose: International 
4.2.2.1 World Health Organisation 
In terms of international evaluation, decisions made by the World Health 
Organisation (WHO) (United Nations. World Health Organisation), the MHRA (United 
Kingdom. Medicines and Healthcare Products Regulatory Authority) and the FDA 
(United States of America. Food and Drugs Administration) were reviewed. 
 
The WHO in its publications of Model list of essential medicines for children (WHO. 
WHO Model List of Essential Medicines for Children, 2013) and model formulary for 
children (Bidgood et al (ed.), 2010) provided recommendations of paracetamol 
strengths for three pharmaceutical preparations. The two oral forms were liquid in the 
strength of 25 mg per 1 ml (or 125 mg per 5 ml), and, tablets with varying strengths 
of 100 to 500 mg per tablet.  
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The rectal preparation strength was 100 mg paracetamol per suppository. 
Administration from the rectal route was erratic and was therefore not a 
recommended route (Bidgood et al (ed.), 2010).  
The WHO (Bidgood et al (ed.), 2010) maximum daily limit was four grams while MCC 
was two to three gram based upon body weight for the injection formulation. 
 
The WHO list (Bidgood et al (ed.), 2010) list did not reflect details in respect of dose, 
frequency or maximum daily limit. 
 
4.2.2.2 MHRA (United Kingdom. Medicines and Healthcare Products Authority) 
The MHRA approved dosages for paracetamol were the same as described under 
MCC approved source (chapter 4.2.1). 
 
4.2.2.3 FDA (United States of America. Food and Drugs Administration) 
The FDA (United States. Food and Drugs Administration, Organ-Specific Warnings, 
2009) stipulated a maximum daily dose for over-the-counter paracetamol 
(acetaminophen) as not exceeding four gram daily with a single dose not to exceed 
one gram. The FDA (United States of America. Food and Drugs Administration) 
advisory panel recommended single dose range of 160-480 mg for children aged two 
to eleven years with no more than five doses in a 24 hour period (Brunton, 2011).  
 
4.3. Overdose or poisoning with paracetamol 
There was no difference in overdose treatment for adults or children (South Africa. 
Medicines Control Council, Standardised text, 2010 and Brayfield (ed.), 
Acetylcysteine, 2014). Acute overdose is not intentional in children (Gazarain, Drew 
and Bennett, 2014) but chronic use or supradoses have resulted in “unintentional 
overdose” (Brayfield (ed), Paracetamol, 2014)). 
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The recommended treatment of overdose was similar between MCC and its 
accepted source. When reviewed further, the differences were in the administration 
time of activated charcoal, the NAC intravenous diluents and NAC administration 
time as summarised in table 4. 
 
Table 4: Differences of paracetamol overdose treatment 
A summary of the differences of paracetamol overdose treatment recommended by 
MCC and Martindale (Brayfield (ed.), Acetylcysteine, 2014) 
Detail MCC Martindale 
Activated charcoal: time of 
administration (hours) 
4  1 
Intravenous diluents for NAC Dextrose solution 5% glucose solution 
Administration period (minutes) 15 60 
 
The longer infusion time was thought to reduce the incidence and severity reactions 
(Acetylcycteine (acetadote) for acetaminophen, 2005).  
 
A note was made for the adjustment of the intravenous fluid for children weighing 
less than 40 kg with no indication on whether the volume should be adjusted up or 
down (South Africa. Medicines Control Council, Standardised text, 2010). 
Intravenous volume adjustment for children should be halved (United Kingdom. 
BNFc, April 2014). 
 
The dose for oral NAC treatment was the same, though the Martindale (Brayfield 
(ed.), Acetylcysteine, 2014) recommended administration as a 5% solution. 
Methionine is an alternate option but was not available on the South African market 
(MIMS, May 2012). 
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Overdose in pregnancy was addressed as recommended (Wilkes, Clark and Herrera 
, 2005 ) treatment but not addressed in MCC 2010 guideline (South Africa. Medicines 
Control Council, Standardised text, 2010). Pre-pregnancy body weight should be 
used to determine toxic levels with actual pregnant body weight to calculate NAC 
dose. 
 
Overdose treatment is a medical emergency (Rossiter (ed.), 2012); however, the 
recommendations from the DoH (South Africa. Department of Health) and Goodman 
and Gilman (Bruton (ed.), 2011) were not included in this research project in respect 
of overdose treatment. 
 
Intravenous paracetamol overdose resulted from dosage errors but rarely have 
resulted in substantial overdose (Brayfield (ed.), 2014). 
 
No reported overdosage from rectal administration was found during the literature 
review. 
 
The interval to initiate NAC treatment is important (Brok, Buckley and Gludd, 2006) 
with the rate of administration not a deciding or contributing factor in the successful 
overdose treatment outcome. The concentration of the solution to be used for dilution 
needs to be clarified in the guideline issued by MCC (South Africa. Medicines Control 
Council, 2010) to determine if there is any significance to using either dextrose or 
glucose solution as the intravenous diluent.  
 
4.4 Medical device 
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The MCC had made allowance for the regulation of medical devices (South Africa, 
Medicines and Related Substances Act 101) but these have not yet been 
implemented as regulations need to be finalised.  
No legislation requirements existed that liquid preparations must include a medicine 
measure which could deliver either a 2,5 or 5 ml dose, either in the pack of at 
dispensing stage. 
 
Thus validation of volume delivery was confirmed, via experimentation on twelve 
devices, by the researcher and author as medical devices had to be either purchased 
or provided to the caregiver when the preparation was dispensed. Results are 
recorded under Appendix 9. 
 
The two standard marked medicines measures, graded plastic teaspoons, provided 
the same volume. When the equivalent was determined when compared with 
syringes of 3 ml, 5 ml (two different brands) and 10 ml, the volume in the syringe was 
approximately 0,5 ml above the medicine measure marking.  
 
Three droppers evaluated were unsuccessful as the rubber suction was ineffective to 
allow the correct volume to be drawn up in one single draw or even repeatedly.  
 
The two household teaspoons provided differing volumes with one providing 4 ml 
while the other 2,5 ml. The tablespoon used provided a volume of 10 ml.  
 
The medicine measures and syringes provided the same volume delivery and it could 
be assumed they were correct as the volume from one device is equivalent to the 
other. Droppers with rubber plastic suctions and household items did not provide the 
same volume of 5 ml which is the recommended dose delivery volume. 
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Medical devices must be provided with paracetamol liquid preparations in the UK 
(United Kingdom. Medicines and Healthcare Products Regulatory Authority) and USA 
(United States of America. Food and Drug Administration). 
 
4.5 Products 
4.5.1 Paracetamol Preparations 
A total of 27 product labelling were evaluated. 88,88% were oral preparations, 
45,83% of which were liquid preparations and 54,17% available as solid dosage 
forms. The remaining preparations were a common product labelling for the 
suppositories and two separate injectable strengths. Consolidated data can be found 
under appendices 10 & 11. 
 
The reviewed product labelling, or package insert, is the only officially approved 
source of information by the MCC (South Africa. Medicines and Related Substances 
Act 101 and Medicines Control Council, Guideline Package insert for Human Use). 
 
4.5.1.1 Liquids 
Ten of the eleven preparations contained 120 mg per 5 ml with the eleventh strength 
of 0,6 g per 0,6 ml claiming to be an infant drop preparation. 
However, only one product reflected a dose for children under the age of 3 months 
and was also indicated for use in older children. 
 
Analysis of the various components of the dosing information revealed that all eleven 
product labelling had the age group of three to twelve months; seven products had 
indicated the age groups of one to five years and six to twelve years, two products 
reflected one to six years and seven to twelve years. One product had reflected the 
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age groups as one to two years and three to six years and then six to twelve years; 
the latter in common with the other products. The last product had reflected the age 
groups as one to four years, five to eight years and nine to twelve years. None of the 
products reflected 12 years and older age group. 
 
The recommended dosage ranged from 60 to 480 mg, or 2,5 to 20 ml, per single 
dose across the age groups. 
The starting dose was 60 mg for four products while six reflected a range of 60 to 
120 mg. Two products have a single dose of 120 mg while eight products have a 
range of 120 to 240 mg. One product has a single dose of 240 mg; one had a range 
of 240 to 360 mg, while the remaining eight products have a range of 240 to 480 mg. 
 
The frequency of administration reflected for two products were four hourly, one 
product had a frequency of four to six hourly while the recommended frequency for 
eight products was six to eight hours. 
 
One product had not listed a maximum daily limit within 24 hours with differing 
maximum limits reflected across the balance of the products.  
Seven of the ten products had a maximum of 480 mg while three products reflected 
half this value at 240 mg for the age group of three to twelve months. Where the age 
group was set at one to five years, six products reflected a maximum of 960 mg. In 
the similar age group of one to six years the one product indicated the maximum as 
480 mg whilst the other was double at 960 mg.  
For the age group of six to twelve years, the maximum set was 1920 mg for six 
products. In the similar age group of seven to twelve years, the one product had a 
maximum limit of 960 mg while the other was doubled.  
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The one product that had a narrower age group band reflected the maximum at 480 
mg for one to four years, 960 mg for five to eight years and 1440 mg for nine to 
twelve years.  
 
4.5.1.2 Tablets 
A total of thirteen solid dosage forms were evaluated which included an effervescent 
formulation. Over 92% of the products had 500 mg paracetamol per tablet or capsule 
with 125 mg per tablet for the remainder of the product aimed specifically for children. 
 
From eleven products, 81,81% reflected the age group of six to twelve years. Only 
18,18%, or two products, reflected the wording for children 12 years and older with 
90,9% indicating an adult dosage. As the labelling specially indicated a younger 
group it was assumed that the adult dosage would be applicable for children twelve 
to eighteen years of age. 
 
The recommended dosage was half to one tablet, or 250 mg to 500 mg, for the age 
group of six to twelve years in 81,81% of the products whilst 54,54% indicated that 
the tablet was not recommended for children under six years. The recommended 
dose for 90,90% in the age group adults, or children over twelve years was one to 
two tablets. However 9,09% indicated paracetamol should not be used for children 
under twelve years whilst the same percentage had a dose of two tablets. The 
effervescent tablet had a dose of half a tablet but the tablet had no breakline which 
could lead to incorrect dosing (Bachynsky, Wiens and Melnychuk, 2002). 
 
In terms of administration frequency, 9,09% had a three hour interval with a 
recommendation of one tablet, 9,09% had no frequency and 9,09% had a six to eight 
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hourly interval. A four hourly interval was recommended by 27,27% while 54,54%, or 
double, recommended a four to six hourly administration. 
 
The daily maximum limit recommended for six to twelve years was 2 g as reflected by 
72,72% while 9,09% had no limit indication. The maximum reflected by 81,81% was 
4 g for children above twelve years while another 12,18% had no daily limit.  
 
The capsule formulation had a restriction that it should not be used in children 
younger than nine years, with a narrow age group of nine to twelve years and 
maximum of 2 g; however, no frequency was specified. In children above twelve, the 
details corresponded to the tablet of one to two capsules with a daily maximum of 4 g 
and a four hourly administration frequency. 
 
The dedicated children formulation had the age group of one to five years with an 
administration of one to two tablets administered four hourly and a maximum of 1 g 
for a period of five days.  
 
4.5.1.3 Suppository 
The dosing information was reflected on a common leaflet for both rectal 
preparations with the age group from 3 months up to 5 years only. The administration 
frequency was six to eight hourly and a maximum of 500 mg for the age group of 
three months to twelve months and 1 g for one to five year old.  
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4.5.1.4 Injection 
The same company marketed the intravenous preparations where weight was used 
for dose calculation with a minimum of four hours between doses and a maximum of 
60 mg/kg for children older than one year and with a body weight of 33 kg or less. 
For children over 33 kg, the daily maximum was not more than 4 g. The dose was the 
same across all ages of 15 mg/kg. 
 
4.5.2 Comparisons 
4.5.2.1 Comparison of the different ZA formulations 
Based on a generalisation of the product labelling, there were some common areas 
within the age group, frequency of administration and the maximum allowed as 
summarised in Table 5. 
 
In the age group of three to twelve months, the dosing frequency was the same for 
liquid and rectal administration of six to eight hours. The dosage range for the liquid 
was 60 to 120 mg whereas rectal dose was 125 mg. The maximum daily limit was 
480 mg for liquids and 500 mg for suppositories. The maximum limit set for the 
intravenous preparation was 2 g with dose calculated on body weight. There were no 
dose recommendations discrepancies for the solid dosage form set at 4 g within 24 
hours. 
 
For one to five years, the similarity across the liquid, solid (tablet) and suppository 
preparations was the maximum daily dose of 960 mg for the liquid and 1 g for the 
solid and suppository formulation. The dosing frequency for liquids and suppositories 
was six to eight hourly while the tablets were more frequent at four to six hourly. The 
dose for tablets and liquids were similar at 125 to 250 mg and 120 to 240 mg 
respectively. The suppository dose recommended was 250 mg.  
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Table 5: Comparison of different formulations in ZA 
A generalised representation from the product labelling of the various paracetamol 
dosage forms on the South African market. 
 
Label 
information 
3-12 months 1-5 years 6-12 years 12-18 years 
LIQUID 
Dose (mg) 60-120 120-240 240-480 Not reflected 
Administration 
Frequency 
(hourly) 
6-8 6-8 6-8 
Daily 
Maximum 
Limit (g) 
0,480 0,960 1,920 
SOLID 
Dose (mg) Not 
recommended 
125-250 250-500 500-1000 
Administration 
Frequency 
(hourly) 
4-6 4-6 4-6 
Daily 
Maximum 
Limit (g) 
1,000 2,000 4,000 
RECTAL 
Dose (mg) 125 250 No 
recommenda-
tion 
No 
recommenda-
tion Administration Frequency 
(hourly) 
6-8 6-8 
Daily 
Maximum 
Limit (g) 
0,500 1,000 
INTRAVENOUS 
Dose (mg/kg) At discretion of 
physician 
15 15 15 
Administration 
Frequency 
(hourly) 
4 4 4 
Daily 
Maximum 
Limit (mg/kg) 
60 60 60 or 4 g 
 
In the six to twelve year group, the dose was 240 to 480 mg for liquids and 250 to 
500 mg for solid formulations. The maximum daily dose for the liquid was 1920 mg 
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while of the tablet was 2 g. Thus dose and maximum daily intake were similar for the 
liquid and solid formulations. The difference was the dosing frequency with the liquid 
administered less frequently at six to eight hourly intervals when compared to the 
tablet which was administered at four to six hourly intervals.  
 
Both the intravenous and solid forms had a maximum daily limit of 4 g with a 
minimum dose frequency of four hourly for children twelve to eighteen years.  
 
Individual differences were specific for the various dosage forms and were discussed 
under chapter 4.5.1. 
 
4.5.2.3 Comparison to DoH (South Africa. Department of Health) 
The dosage as recommended by the South African DoH in their standard treatment 
guidelines at primary level (South Africa. Department of Health, Standard treatment 
guidelines and essential list, primary care, 2008) and hospital level (paediatric level) 
(South Africa. Department of Health, Standard treatment guidelines and essential 
medicines list for South Africa, Hospital Level paediatrics, 2013) differed from the 
MCC approved labelling in respect of age groups.  
 
At primary level the dose was reflected using both weight and age. There is a clear 
indication that paracetamol dose must be calculated based on weight for children 
under 6 months. The primary level reflected the dose based on an ‘infant’ formulation 
which was not listed on the procurement list (South Africa. Department of Health, 
Essential Medicines Programme, Essential Medicines  catalogue, 2014). 
 
The DoH (South Africa. Department of Health) documents did not confirm if the 
intravenous form could be used. 
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4.5.2.2.1: Oral 
Upon comparison of the product labelling to the DoH (South Africa. Department of 
Health) recommendation, the product labelling had 4 age group bands whereas the 
DoH had nine age bands with the split focussed more in the younger age group. 
Comparison of age group, dose frequency and maximum daily dose are reflected in 
Table 6. 
 
Table 6: Comparison of DOH recommendation to product labelling: Oral 
The tabulation was a comparison of the DoH (South Africa. Department of Health) 
recommendation to the generalised product labelling (shaded in tabulation) for the 
oral dosage form (liquids and tablets). 
 
DoH  DoH Label-
ling 
DoH Label
-ling 
Common DoH Label-
ling 
Label-
ling 
Age Dose (mg) Frequency 
(hours) 
Maximum 
(dose) 
Maximum (mg) Age 
1-3 months 48 none 4-6 none 4 doses 192 none none 
3-6 months 60 60-120 4-6 6-8 240 240-480 3-12 
months 6-12 
months 
96 4-6 384 
1-3 years/ 
18 months – 
3 years 
120 120-
240 
4-6 6-8 480 480-960 1-5 
years 
3-5 years 180 4-6 720 
5-11 years 240 or 
250 
240 or 
250 
4-6 6-8 or 
4-6 
960 or 
1000 
960-
1000 
6-12 
years 
11-15 years 500 Up to 
1000 
4-6 4-6 2000 4000 Adult 
Adults Up to 
1000 
4-6 4000 
 
The DoH had a dosage for children up to 15 years. Thereafter the adult dose was 
recommended.  
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The DOH had a dose for one to three months while this was not reflected on product 
labelling which resulted in the first difference. The dose was 48 mg. The second 
differentiation was the ages between three and twelve months. The DoH differed 
from product labelling to reflect three to six months old with the lower dose of 60 mg 
as indicated on the product labelling with the same daily maximum dose. For the six 
to twelve month old, the DoH reflected a changed dose of 96 mg which yielded a 
daily dose of 384 mg when the labelling reflected a dose of 120 mg and a maximum 
of 480 mg. For these two age groups the DoH had an administration frequency of 
four to six hours while the labelling suggested a longer period between 
administrations of six to eight hours.  
 
For older age groups the DoH was consistent in the daily maximum of 4 doses with a 
suggested four to six hourly administration frequency. Maximum of four doses was 
common across both the labelling and DoH recommendations for liquid formulations. 
 
A third segregation was the age groups of 12 months to five years. The DoH has 
divided this into two; namely, twelve months to three years and three to five years. 
The lower dose of 120 mg concurred for one to three years. The DoH suggested 180 
mg whereas that on the labelling was higher at 240 mg which yielded maximum 
doses of 480 mg for the lower age group but 720 mg or 960 mg for the DoH and 
labelling respectively. 
 
The DoH had an age group of five to eleven years whist the labelling was six to 
twelve years, fourth difference. The suggested dose was the same for both which 
produced the same maximum dose.  
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The fifth difference was that the DoH reflected the age group of eleven to fifteen 
years which was nonexistent on the product labelling. The dose recommended was 
500 mg with a maximum daily dose of 2 g. 
 
4.5.2.2.2 Rectal: 
The DoH and product labelled differed in the dose, frequency and maximum limit as 
summarised in Table 7. 
 
Table 7: Comparison of DOH recommendation to product labelling: Rectal 
The tabulation was a comparison of the DoH (South Africa. Department of Health) 
recommendation to the generalised product labelling (shaded in tabulation) for the 
rectal dosage form. 
 
DoH DoH Label-
ling 
DoH Label-
ling 
DoH Label-
ling 
Label-
ling 
Age Dose (mg) Frequency (hours) Maximum limit (mg) Age 
3-12 
months 
62,5-
125 
125 4-6 6-8 250-500 500 3-12 
months 
1-5 
years 
125-250 250 4-6 6-8 500-
1000 
1000 1-5 
years 
6-12 
years 
250-500  4-6 n/a 2000 n/a n/a 
 
The age group of three to twelve months and one to five years was the same. 
The dose recommended by the DoH was 62,5 mg to 125 mg, administered four to six 
hourly with maximum limit of 250 to 500 mg dependent on the dose administered for 
three to twelve months. The labelling only had one dose of 125 mg, administered 
every six to eight hours thus a maximum of 500 mg.  
 
The suppositories did not have a dividing score thus a 60 or 62,5 mg dose raised the 
concern of the management of dosing accuracy within a hospital or home setting. 
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The American Academy of Pediatrics Committee had indicated that dividing 
suppositories to provide lower doses may not provide predictable doses (AAPC, 
2001). 
 
The DoH recommended 125 to 250 mg for one to five years every four to six hours 
with a maximum of 1 g based on the highest dose. The labelling dose was 250 mg 
administered six to eight hourly with a maximum of 1 g. 
 
The DoH added six to twelve years old group with a recommended dose of 250 to 
500 mg every four to six hours thus a maximum of 2 g concurring with solid 
preparation recommendation. 
 
4.5.2.3 Comparison to MCC accepted source: 
4.5.2.3.1 Oral: 
When the product labelling and MCC accepted source were compared, the labelling 
had four age group bands whereas the source had nine bands. However unlike the 
DoH (South Africa. Department of Health) where the split was over younger age 
group, the source had a two year gap for most of the ranges as depicted in table 8.  
 
Similar to the DoH, the frequency was four to six hourly with a maximum of four 
doses in a day with the exception of one to three month where the frequency was 
eight hourly. 
 
The recommended single dose for this age group was 30 to 60 mg which made this 
the lowest administered dose. The maximum was 120 to 240 mg.  
The second age range concurred with the DOH recommendations. 
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The third differed from the DoH in that the age group was narrowed to six to twenty 
four months when compared to the DoH of six to thirty six months. The dose was 120 
mg with a maximum of 480 mg. 
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Table 8: Comparison to MCC accepted source. 
The tabulation was a summary of the recommended dose strength, the frequency of 
administration and maximum daily limit from the MCC accepted source, the DoH 
(South Africa, Department of Health) recommendation and the generalised product 
labelling for the oral dosage forms. 
 
Age 
Months 
or years 
Dose (mg) Frequency (hours) Maximum (dose per 
day) 
MCC DoH Label MCC DoH Label MCC DoH Label 
1-3 30-60 48 None 8 4-6 none 4 4 4 
3-6 60 60 60-120 4-6 6-8 
(liquid) 
or 4-6 
(solid) 
6-12 120 96 
12-24 120 120-
240 2 180 
3 180 
4 240 
5 240-
250 6 240-
250 
240-
480 7 
8 360-
375 9 
10 480-
500 11 500 
12 480-
750 
Adult/ 
500-
1000 
4-6 
13 
14 
15 
16 500-
1000 
Adult 
17 Adult 
18 
 
The fourth band was two to four years with a dose of 180 mg and a maximum of 720 
mg which coincided with the DoH recommendation for three to five years. 
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The fifth band was four to six years with a dose of 240 mg and a maximum of 960 mg 
which correlated to the labelling maximum single dose for one to five years. 
The sixth band was six to eight years with the dose of 240 mg or 250 mg and a 
maximum of 960 mg or 1 g. This coincided to five to eleven years DoH 
recommendation.  
The seventh band was eight to ten years with 360 to 375 mg dose and a maximum of 
1440 to 1500 mg. 
The eighth band was ten to twelve years with 480 to 500 mg dose and a maximum of 
1,920 to 2 g. 
The last band was twelve to sixteen years with a dose of 480 to 750 mg and a 
maximum of 1,920 to 3 g. 
 
4.5.2.3.2 Rectal: 
The age groups, the dosage, frequency of administration and maximum limit 
suggested by the DoH coincided with the MCC reference with the exception of two 
details. The first was a lower dose of 60 mg suggested for three to twelve month old 
in the source while the DoH recommended 62,5 mg. The second point was the last 
age group where the source began with five years and the DoH with six. The MCC 
source removed doubt on treatment for children between the ages five to six years. 
 
4.5.3 International product review 
The full prescribing information for TylenolTM from the United States indicated that 
children over 12 years of age should be given the same as the adult dose and that 
there was no FDA approved dose for children younger than 2 years. 
 
PanadolTM from the UK was available in a variety of strengths as solid dosage form 
and was not recommended for children under 6 years, the same as South African 
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labelling. A narrower age band as per MHRA recommendation for liquid preparations 
had not been defined. This could be attributed to the difficulty of administration of ¾ 
tablet as the tablet scoring would then have to be cross score lines to provide 375 mg 
paracetamol per dose (Bachynsky, Wiens and Melnychuk, 2002). 
 
Another product, Boots Paracetamol 3 Month PlusTM was reviewed. The 
recommended doses are up to six years of age which corresponded to the dose and 
age group as described in chapter 4.2.1. 
 
4.5.4 N-acetylcysteine 
 
For the intravenous treatment of overdose, the NAC specific labelling (MIMS, May 
2012) corresponded to the MCC standardised texts including the vague statement 
that volume needs to be adjusted in children with no special dose recommendation. 
 
The review of paracetamol labelling information in respect of overdose had reflected 
no distinction between the various pharmaceutical formulations as overdose is a 
component of distribution, metabolism and elimination of paracetamol occurring 
following absorption. 
 
27 paracetamol products were evaluated. Only 25,93% (7 products) met the MCC 
standardised text requirements (Medicines Control Council, Standardised text, 2010) 
while 51,85% did not conform to the requirement. Labelling information could not be 
sourced for 11,11% of products whilst 11,11% were no longer listed in MIMS (MIMS, 
August 2013). Pharmacies did not stock all preparations at any given moment due to 
shelf space resources constraints. 
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TylenolTM labelling detailed the full dosing requirement as per the MCC requirement. 
In the United Kingdom, reference was made to treatment as soon as possible and 
the use of charcoal and NAC but no specific details were listed on the actual product 
labelling. 
 
The labelling details as prescribed by the MHRA (United Kingdom. Medicines and 
Healthcare Products Regulatory Authority) focussed on the ingredient, paracetamol, 
and not on the overdose ingredient NAC. In addition, paracetamol overdose was an 
emergency condition that required treatment in a clinical environment (Rossiter, 
2012).  
 
4.6 Restriction of sale 
The restriction of sale (South Africa. Medicines and Related Substances Act 101, 
Schedules) is based on the total quantity per pack and on the dosage form. Products 
classified as OTC or Schedule 0 (South Africa. Medicines and Related Substances 
Act 101, schedules), met the conditions as specified in the Schedules (South Africa. 
Medicines and Related Substances Act 101,. 
 
In the United States, over-the-counter product were only available for age 2 years 
and older (TylenolTM prescribing information) and there was a restriction of pack size 
as in most other parts of the world (Waitemata District Health Board, 2012). 
 
The United Kingdom had a firmer control on pack size restrictions. They had allowed 
16 tablets per pack to be sold by a general dealer, a pharmacy pack size not to 
exceed 32 tablets and pack sizes above 100 must be prescribed (Hawkins et al, 
2007). Furthermore, the MHRA (United Kingdom. Medicines and Healthcare 
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Products Regulatory Authority) had initiated a sale restriction of two packs per sale. 
No other regulator had instituted this control of restriction. 
 
4.7 Child 
The Children’s Act (South Africa. Children’s Act 38) concurred with the National 
Health Act (South Africa. National Health Act 61) to define the age of a children to be 
anyone eighteen years or younger. 
 
The United Kingdom used the terminology paediatric population where the definition 
of age coincided to ZA (United Kingdom, Medicines and Healthcare Products 
Regulatory authority, Medicines for Children). 
 
The WHO model formulary for children was intended for children up to the age of 12 
years (Bidgood et al, 2010). This principle was adopted by the FDA (TylenolTM 
prescribing information). 
 
4. 8 Surveys 
The surveys were conducted over a period of four weeks beginning 20th March 2014 
until the 15th April 2014 by the researcher conducting face-to-face interviews with all 
respondents. Prior to the actual survey, various general dealers and pharmacist were 
approached personally or via telephone to request their assistance in the research. 
The respondents were given the survey forms to complete and clarification provided 
by the researcher where necessary. When requested, the research completed the 
form but read the form together with the respondent before addressing each point. 
The time varied for each survey as a result of other general discussions with the 
period for the survey varying from 10 minutes to 30 minutes per survey. 
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Common questions asked of caregivers and pharmacists were on dose 
recommended, the frequency of administration, the review of product labelling and 
whether a medicine measure was considered. Please refer appendices 2 – 5 for a 
template of the survey documentation. Appendices 13 and 14 provide a consolidation 
of the responses received from all the respondents. 
 
The dose recommended by 80% of pharmacists was in millilitres where the dose was 
per product labelling. 20% of pharmacists recommended using a teaspoon while 20% 
recommended the solid form for children older than six years.  
 
80% of caregivers indicated that they reviewed the product labelling while 20% used 
paracetamol as recommended by their pharmacist. 40% of caregivers used a 
teaspoon to administer liquid paracetamol while 60% indicated that they administered 
the product in millilitres. The doses administered met the product labelling but was on 
the lower end for all age groups. 
Neither pharmacist nor caregiver exceeded 10 ml per dose while labelling indicated a 
dose of up to 20 ml for the age group of six to twelve years. 
The labelling frequency of administration was six to eight hourly with a six hourly 
recommendation by 80% of pharmacists while 20% relayed the doctor’s instructions 
to the caregiver.  
Doses administered by caregivers ranged from four to eight hourly. The distribution 
was 30% each at four and eight hours, while 40% administered paracetamol at six 
hourly intervals. 
 
70% of caregivers and 40% of pharmacists had reviewed the labelling in the last 
month. All pharmacists had reviewed the labelling within the last twelve months while 
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the figure for caregivers was 80%. 20% of caregivers previously reviewed the 
labelling more than twelve months ago. 
 
Household items were the preferred device for administration of paracetamol liquid 
preparations. 60% preferred a teaspoon while 30% used a tablespoon. Only 10% 
used a syringe. None of the respondents used a dedicated medicine measure. 100% 
of pharmacists which served the low income groups handed out medicines measures 
to caregivers whereas pharmacists in the middle suburb sold medical devices as 
separate items. 
 
Caregivers did not inform any healthcare profession when they thought paracetamol 
was ineffective in 60% of the cases which implied that there was a lack of 
pharmacovigilance reporting. 
 
4.9 Hypothesis testing 
The dependent variable of MCC information was based on MCC’s accepted source 
and the independent variable assessed were the product labelling, use in practice by 
caregivers and the pharmacist recommendations within the private sector and the 
DoH (South Africa. Department of Health) treatment guidelines for public sector 
recommendations.  
 
Parameters assessed were age, dose, frequency and maximum daily limit across the 
different dosage forms based on the findings reported under chapter 4. The results 
were coded 0 or 1 as described under chapter 3.2. The comparisons are described in 
tables 9 and 10 below. 
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Table 9: Product labelling evaluation 
The score rating for the determination of conformance of product labelling to MCC 
accepted recommended, frequency of administration and daily maximum limit for 
children. 
 
Dosage form Age Dose Frequency Maximum 
Liquid 0 0 0 1 
Tablet 0 0 0 1 
Rectal 0 0 0 1 
Intravenous 1 1 1 1 
 
Therefore the only dosage form that met the regulator standard was the intravenous 
preparation accessible in a clinical setting. 
 
The rectal form was available from pharmacy only and met the maximum daily dose. 
Age and dose did not conform to the standard. 
 
The liquid and solid dosage forms were easily accessible to caregivers and met the 
maximum dose only. Age and dose did not meet the standard.  
Medical device use was not assessed as a parameter due to lack of legislation 
enforcement. 
 
As more than 50% of pharmacists and caregivers referred to the product labelling, it 
confirmed the importance of product labelling. 
 
Therefore, for the private sector, 7,41% of the labelling met regulator standards. 
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Table 10: DoH recommendation evaluation 
The score rating for the determination of conformance of DOH (South Africa, 
Department of Health) recommendations to MCC accepted recommended, frequency 
of administration and daily maximum limit for children. 
Dosage form Age Dose Frequency Maximum 
Liquid 0 0 1 1 
Tablet 0 0 1 1 
Rectal 1 1 1 1 
Intravenous n/a n/a n/a n/a 
 
The rectal form met all the regulator conformance parameters. The differences of 
dose (under 4%) and age (five years and six years had to same dose) were 
acceptable. 
 
All dosage forms met the frequency and maximum requirement. However liquid and 
tablet preparations did not meet the dose or age parameter. 
 
Medical devices were procured by the department (South Africa. Department of 
Health, Medical and Pharmaceutical contracts, 2014) but the practice setting was not 
established in this research project. 
 
Therefore in the public sector, the only dosage form to meet the regulator standard 
was the rectal preparation. All other dosage forms did not meet the requirements 
although the DoH had eight age group bands. 
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In terms of consideration of children, neither the private nor the public sector met the 
definition of the eighteen years of age requirement.  
 
It is concluded that the null hypothesis is met. 
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5. Conclusions and/or Recommendations 
 
Paracetamol is the most used drug (South Africa. Department of Health, Tenders 
liquids and solid dosage forms, 2012 and IMS, 2014) available both over-the-counter 
and in pharmacy used by both children and adults (Brayfield (ed.), 2014). This 
research focussed on the use of paracetamol in children on the basis of their 
vulnerability when administered medicines by caregivers. 
 
An extensive review of the South African legislation with specific reference to 
paracetamol yielded information on the strength per unit dose, pack size restriction, 
point of sale, labelling requirements and overdose treatment. There was no specific 
suggestion to dosing or labelling requirements in children apart from alcohol content 
for oral medicines (Medicines Control Council, Alcohol Content, 2003). 
 
The paracetamol recommendations from the national Department of Health of South 
was reviewed as the department of health are responsible for legislating the control 
of medicines in addition to principles governing professional practice of all healthcare 
providers within South Africa. 
 
Specific product labelling was reviewed as MCC scrutinized all labelling at the time of 
assessment prior to granting a marketing authorisation (South Africa. Medicines and 
Related Substances Act 101, Section 15). Subsequent labelling changes are initiated 
by the marketing authorisation holder or in very rare instances as a result of a MCC 
directive (Medicines Control Council, Medicines Safety Alert, Cough and Cold 
preparations, 2011). MCC (Medicines Control Council, Package inserts for Human 
use, 2014) had initiated that product labelling should reflect registration and 
amendment dates on the package insert. However; would the community pharmacist 
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or even a caregiver realize the value of this information to them warrants further 
investigation as it indicates when last the package insert was updated by the 
pharmaceutical company. 
 
Paracetamol is well-known and well-established molecule should be referenced to 
The Complete Drug Reference, or simply Martindale as per MCC (Medicines Control 
Council, Package inserts for Human use, 2010) accepted reference. Therefore 
changes made in Martindale must be filtered down to product specific labelling. The 
ultimate aim is to provide users including caregivers and healthcare professionals 
with updated safety information (Gray, May 2014). 
 
Paracetamol in liquid preparations are available only in two strengths in South Africa. 
This correlated to the 2009 FDA (United States of America, Food and Drugs 
Administration) ruling that paracetamol liquid preparations be available in limited 
strengths to minimise dosage errors (Food and Drugs Administration, 2009). 
 
In 2011, the MHRA (United Kingdom. Medicines and Healthcare Products Regulatory 
authority, 2011) made a ruling to narrow the age band for liquid preparations to 
ensure that younger children were not overdosed and that older children were not 
under dosed. The MHRA recommended doses, can be administered and used in 
children based on the 120 mg/5 ml strength formulation available in ZA, as 
preparations reflected doses up to the age of twelve and can be extended to include 
dosing instructions for children older than twelve years. 
 
As a consequence of the MHRA decision, the United Kingdom recommended dose 
was revised in the British National Formulary. The dose was reflected in milligram 
and not limited to a particular dosage form. The MHRA dose revision affects the 
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tablet formulation but has not yet been incorporated onto the product labelling 
(PanadolTM SmPC) which could be due to a lack of the MHRA directive on 
addressing the tablet formulations. There were only two marketed strengths for solid 
preparations in ZA. For the common 500 mg strength, there was conflicting 
recommendations in administration to children six to twelve years, generally the 
same dose was recommended for six to twelve year olds with fewer than twenty 
percent of the labelling specifically addressing a dose for children over the age of 
twelve. 
 
Paracetamol strengths for rectal or intravenous preparations were similar to that 
available internationally in terms of dose and frequency of administration. 
 
There was commonality for the maximum daily doses across all dosage forms. 
Children doses ranged from 60 mg to 4 g from birth until eighteen years of age. Adult 
doses were recommended for children over fifteen by the DoH at primary and 
hospital level (South Africa. Department of Health, 2008 and 2013) and over sixteen 
in Martindale (Brayfield (ed.), Paracetamol 2014). It was identified that product 
labelling does not adequately address the children age group of twelve to eighteen 
years in South Africa. 
 
Finding of the research revealed that administration frequency differed across 
dosage forms and even across the same dosage form notably for liquids in South 
Africa. Martindale (Brayfield (ed.), Paracetamol, 2014) and the DoH (South Africa. 
Department of Health) had a rectal dose for children up to the age of twelve whilst 
the product labelling in ZA terminated at five years.  
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There were differences in the age group bands and therefore there were dose 
differences across the different preparations marketed in ZA (MIMS, May 2012). This 
was applicable when comparing the MCC approved product labelling to the DOH 
recommendations. The DoH recommendations were similar to that ascribed in 
Martindale (Brayfield (ed.), Paracetamol, 2014) but differed to the approved labelling.  
 
There are eleven official languages in South Africa; however, labelling must be 
captured in “English and one other official language” (Medicines and Related 
Substances Act 101, Regulations 8, 9 and 10) with Afrikaans being the other 
language based on previous legislation. Apart from being instructed by healthcare 
professionals at the time of dispensing, there is no further progress to inform illiterate 
care-givers on the safe administration of medicines to children. 
 
Paracetamol’s narrow therapeutic index makes it necessary to inform caregivers and 
healthcare professionals of the signs, symptoms and treatment regimen as a result of 
a paracetamol overdose. Due to the seriousness of hepatic failure associated with 
paracetamol overdose (Brayfield (ed.), Paracetamol, 2014), treatment had been 
classified as a medical emergency worldwide. However internationally there was no 
consensus on the type of treatment, intravenous or oral, or the rate of administration 
when using acetylcysteine. However, consensus exists that treatment of paracetamol 
overdose should begin as soon as possible. 
 
The United Kingdom was the only country that had a limitation on the quantity that 
could be sold in a single purchase and limited pack for pharmacist initiated therapy 
(PAGB, 2013). However given that paracetamol are freely available at general store 
outlets in South Africa, the practicality of a similar recommendation for South Africa 
might not be feasible. The Advertising Standards Authority code in South Africa(ASA 
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2014) did not curb the sale of medicines either in terms of age or pack size to 
children in South Africa. However, there is a limitation on the sale of medicines to 
children over the age of fourteen in pharmacy (South Africa, Medicines and Related 
Substances Act 101, Section 22A). 
 
From the surveys conducted during the research, it was established that product 
labelling does play an important role when pharmacists or caregivers prescribe or 
administer medicines to children as the dose is confirmed from the package insert. In 
addition, the survey revealed that caregivers were not aware that a household 
teaspoon and a medicines measure teaspoon did not provide the same volume. The 
medicine measure or the recommended product labelling unit dose is provided in 
volume units of 5 ml. The finding confirmed that a household teaspoon provides a 
volume less than 5 ml; and therefore, it is concluded that children under dosed when 
given liquid paracetamol preparations. Of the caregivers surveyed, none 
administered the tablet to children and was a shortcoming that was not anticipated 
and thus not addressed in the survey questionnaire. The survey revealed that the 
children population in South Africa are being under dosed with paracetamol liquid, 
similar to the finding by Kazouini(Kazouini A et al, 2011). 
 
All surveys were conducted within pharmacies, with no pharmacist indicating that 
they initiated therapy with a suppository and none of the caregivers mentioned the 
rectal form during the face-to-face discussions. There were no modified release 
paracetamol preparations on the market (MIMS, August 2013) 
 
Upon concluding this research, it is noted that product labelling needs to take into 
consideration the recommended target population for the particular drug; and in 
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addition, to address formulations limitations should more than one dosage form exist 
as  is the case with paracetamol.  
 
A recommendation is that the “main panel” wording as stipulated by MCC (Medicines 
and Related Substances Act 101, Schedules) be revisited as caregivers did not 
recognise a drug by its international non-proprietary name, or generic name, but 
were conscious of brand names as observed when the survey interviews were 
conducted by the researcher. Therefore, it was concluded that the boxed warning 
required on the front panel, does not provide any heightened awareness of the 
dangers of overdosing with paracetamol. Furthermore, the definition of a main panel 
in labelling needs to be clarified at this was the only molecule (Medicines and 
Related Substances Act 101, schedules) that had this limitation in South Africa. 
 
A consolidated review of the multiple pharmaceutical forms was enlightening. 
For liquid preparations, the dose was reflected in millilitres while this is not a 
household item. The research conducted has shown that caregivers equated a 
teaspoon to provide a 5 ml dose. 
Fortunately the opportunity has just presented itself to comment on the proposed 
medical devices regulations in ZA. The recommendation will be for the inclusion of a 
medicine measure or equivalent device to be provided with all medical liquid 
preparations sold. 
 
Paracetamol is presented in the same strength in tablet or capsule form to be 
swallowed, as an effervescent tablet to be dissolved just before administration or a 
meltab that could dissolved on the tongue. Yet there is no guidance at which age 
group the solid form may be given to children. As an illustration, one product 
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indicated that it was not recommended for children under the age of twelve but yet 
other preparations reflected a tablet dose for children from six to twelve years.  
 
There was a recommendation that half a tablet be administered on a product 
package insert; but this product did not have a score line to allow for the tablet to be 
broken and to deliver this half a tablet dose. Similarly, it could be concluded that a 
child would find it easier to be given a meltab, which is a thin film, that disintegrates 
in the mouth rather than a tablet to swallow yet the meltab is not recommend for 
children under the age of twelve. This re-emphasizes that the target population 
should be considered during the product design phase and dosage form limitations 
captured on product labelling. 
 
This research project has uncovered the importance of updating product labelling 
especially when the benefit risk ratio is modified or could impact the safe use of a 
product (Medicines Control Council, Safety-related Package insert notifications, 
2014) particularly when a preparation is made available directly to the consumer with 
no healthcare provider intervention. Therefore it is imperative that MCC issue 
consumer directives as practised by other established regulators such as the MHRA 
and the FDA. These consumer directives will provide a clear and unambiguous 
leadership from the regulator in managing the safe and effect use of medicines used 
by the public which it, the MCC, serves to protect. 
 
A limitation was that the research project did not provide any answers of research 
conducted previously to indicate at what age a child might be independent enough to 
use medication without caregiver supervision. The Medicines and Related 
Substances Act 101 (South Africa. Medicines and Related Substances Act 101) 
provided some guidance as it indicated that medication can only be sold to children 
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older than fourteen years but did not address to whom medicines can be sold at 
general dealer outlets. 
 
Another restriction is that no single clause or rule can be assessed on its own and 
that many aspects or clauses need to be taken into consideration when medicines 
are administered to children. It was not possible to address all within this research 
project.  
 
Further investigations should include the review of labelling for products that are 
supplied to the DoH (South Africa. Department of Health) including determining if a 
medicine measure in included in the pack, public sector practice recommendation for 
paracetamol preparations, evaluation of prescribing habits by authorised prescribers, 
re-imbursement trends, and an analysis into the paracetamol overdose treatment in 
South Africa. 
 
It is essential that MCC and the pharmaceutical industry be cognisant of dosage 
recommended for children, their age group breakdown, the differing international 
definition of a child and other international trends especially those that relate to 
effective administration of medicines to children.  
 
The observations noted from the recommended dosage review of the product 
labelling and that used in practice from the results of the survey, is that children are 
not being given the recommended dose as per product labelling. However, product 
labelling does not correlate to MCC’s accepted source. Therefore, children are not 
receiving the correct therapeutic dose of paracetamol. 
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The null hypothesis has been proven and therefore it is concluded that paracetamol 
is not being used or prescribed at the correct therapeutic dose in the children 
population within South Africa.  
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Title:  
Is paracetamol being prescribed and used at the correct 
therapeutic dose in the children population in South Africa? 
 
Introduction 
Paracetamol is first line treatment as an analgesic (treatment of pain) and antipyretic 
(treatment of fever) especially in children (Brayfield). It is one of two1 orally 
administered analgesic and antipyretic available without prescription2 at pharmacies 
or can be purchased from a general dealer store (LexisNexis). Paracetamol was first 
commercialised in 1953 in the United States and subsequently introduced to other 
parts of the world (Sneader). 
 
Although highly effective, paracetamol has a narrow therapeutic index (FDA) and 
therefore needs to be administered to children correctly. Paracetamol is less irritant 
on the stomach lining when compared to non-steroidal anti-inflammatory agents and 
is therefore the treatment of choice in children (Brayfield). 
 
There are options of different pharmaceutical dosage forms for paracetamol. 
Paracetamol is available as a syrup having the strength of 120 mg per 5 ml, as a 
tablet or capsule containing 500 mg, as suppositories containing either 125 mg or 
250 mg per suppository, as melt tabs (or effervescent tablets) containing either 125 
mg or 500 mg per tablet or as a solution for infusion containing 1 g per 100 ml 
(MIMS).  
 
With the different dosage forms containing variable quantities of paracetamol, the 
research will review the current legislation on paracetamol, the therapeutic dose of 
paracetamol and the manner of administration (medical device) to ensure correct 
use of paracetamol preparations in children. 
 
                                                          
1 The other preparation contains aspirin 
2 Prescription is the term used in South Africa and is the same as a script for medicines 
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The focus of the research in children is as a result of the conflicting classification of 
children internationally versus that of South Africa. The reason for this research is to 
increase awareness for the correct and effective use of paracetamol preparations in 
children population. 
 
Hypothesis: 
Paracetamol is effective within a defined therapeutic range however are prescribers 
and caregivers using paracetamol as authorized by regulators. 
 
Methodology 
The methodology for this research will be a mixed methods approach using both 
quantitative and qualitative study. A closed structured survey has been developed 
(attachments 6 and 7) whereby data will be collected. This will ensure data reliability. 
If the participants (respondents) do have additional time, this may present the 
opportunity for continuation into open-ended discussions. It is anticipated that data 
collection will be via completion of the survey form and an audio recording. 
 
The data from the survey will be captured during the interviews. Should open-ended 
discussions take place, these will be captured electronically and summarised in hard 
copy. Aadila Patel will be solely be responsible for collecting the data and will use 
face validity. 
 
The data collection will focus on the dose and medical devices that are used to 
administer the paracetamol preparation to the child. 
 
Data collection sites will be from private pharmacies at different practice settings, 
different social economics groups at pharmacy level and at different retail outlets. 
Data collection will not be conducted in the public sector at this stage due to the time 
limitation to complete the research and the slow progress of authorisation that needs 
to be obtained from the Department of Health. However, any relevant research that 
is available in the public domain will be included in the study. 
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In terms of legislation, data collection will consist of the review of current legislation 
in South Africa and internationally. In addition, there will be a review of the various 
scientific package inserts on the South African market. A comparison will be 
performed against one product from the United States and another from the United 
Kingdom. 
 
Ethical considerations 
Children have been classified as a vulnerable group (ICH). It is important that as 
adults we continually review the safety of medicines, be this from the perspective of 
a caregiver or as healthcare professional. The latter could constitute the delivery of 
effective healthcare or as a component of continuing professional development. 
 
Data collection for this research project will be confidential, although the survey does 
not require any personal information to be shared in respect of any child. 
 
The principle investigator of this research will be Aadila Patel. The focus of the 
research will be practice ethics in terms of responsibility of updating information, if 
required. Clinical ethics (treatment delivery and care) will be considered. The role of 
the regulator will be reviewed to determine if they are responsible for public ethics 
(Ashcroft) and informing the public of new safety information in the effective use of 
paracetamol. 
 
The sponsor3 responsibility in this research project is Pharmaceutical Quality 
Partner. 
 
                                                          
3 Limited to funding only 
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PARACETAMOL SURVEY: CHILDREN 12 YEARS AND UNDER 
 
Pharmacy   Independent    Corporate 
 
Profession:   Pharmacist    Pharmacy Assistant 
   Nurse     Other: 
 
 
1. Do you use paracetamol as first line treatment: 
Yes   No 
 
2. What is the dose that you recommend: 
 
 
3. What is the frequency of the dose: 
4 hours   6 hours   8 hours 
 
4. Do you look at the package insert of the product that is being dispensed: 
Yes   No 
 
5. When last have you looked at the package insert: 
Last month  last 3 months   last 12 months  over 12 months ago 
 
6. Do you hand out a medicine measure: 
No   Yes 
 
7. Do you ask if the caregiver has an adequate dispensing device (medicine measure) to dose 
 the child 
No   Yes 
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PARACETAMOL SURVEY: CHILDREN 12 YEARS AND UNDER1 
 
Caregiver   Parent     Grandparent 
   Guardian    Day caregiver 
 
 
Purchase:   Independent Pharmacy   General dealer 
   Corporate pharmacy   Other: 
 
 
1. Why do you give your child (or child under your care) paracetamol? 
Pain    Fever   Other:  
 
 
2. Do you use paracetamol as first line of treatment: 
Yes   No 
 
3. What is the dose that you give to the child: 
 
 
4. How often do you give the child paracetamol: 
4 hours   6 hours   8 hours 
 
5. Do you look at the package insert of the product before giving the paracetamol syrup: 
Yes   No 
 
6. When last have you looked at the package insert: 
Last month  last 3 months   last 12 months  over 12 months ago 
 
7. How do you give the child paracetamol: 
Teaspoon   Tablespoon  Medicine measure 
Syringe       Other: 
 
 
8. Do you tell the pharmacist or doctor if you think that the product is not working 
No   Yes 
 
9. For how long do you use paracetamol before you go to seek the advice of your pharmacist or 
 doctor 
3 - 5 days   10 days   Other:  
                                                          
1 Age group in line with paracetamol dosage in preparations for children in South Africa 
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CONSENT FORM1 
 
Protocol Title: 
 
Please tick the appropriate answer. 
 
I confirm that I have read and understood the Information Leaflet dated _Nov 2013 v1__ 
attached, and that I have had ample opportunity to ask questions all of which have been 
satisfactorily answered.  Yes  No 
 
I understand that my participation in this study is entirely voluntary and that I may 
withdraw at any time, without giving reason, and without this decision affecting my future 
participation in further research.  Yes  No 
 
I understand that my identity (or that of my child/ren) will remain confidential at all times. 
  Yes  No 
 
I have been given a copy of the Information Leaflet and a copy of a Consent form for my 
records.  Yes  No 
 
FUTURE USE OF ANONYMOUS DATA:   
I agree that I will not restrict the use to which the results of this study may be applied. I give 
my approval that unidentifiable data concerning my person (or of my child/ren) may be 
stored or electronically processed for the purpose of scientific research and may be used in 
related or other studies in the future. (This would be subject to approval by an independent 
body, which safeguards the welfare and rights of people in biomedical research studies)
  Yes  No 
 
 
Participant :________________ ___________________ 
        Signature Name in block capitals 
                                                     
1 To be completed by all participants; healthcare professional and parent/caregiver 
Is paracetamol being prescribed and used at the correct 
therapeutic dose in the children population in South 
Africa? 
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Date ________________ 
  
To be completed by the Investigator (in the presence of the participant). 
 
I the undersigned, have taken the time to fully explain to the above participant the nature 
and purpose of this study in a manner that he/she could understand. I have explained the 
risks involved, the reason for research, as well as the possible benefits and have invited 
him/here to ask questions on any aspect of the survey that concerns them. 
 
 
________________ _Aadila Patel___________ _BPharm____ ________ 
Signature: Name in Block Capitals: Qualification: Date: 
 
 
________________ 
Site name 
 
 
 
2 copies to be completed: 1 for patient and 1 for Principal investigator. 
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Participant Information Leaflet  
 
Protocol Title: 
 
 
 
Principal Investigator’s Name: __Aadila Patel_________________ 
 
Principal Investigator’s Title: __Pharmacist__________________ 
 
Telephone No. of Principal Investigator:  _0217013594_______________ 
 
You are being invited to take part in a clinical research study carried out at [to be 
completed at site]. 
 
Before you decide whether or not you wish to take part, you should read the information 
provided below carefully and if you wish to discuss it with your family, friends or 
pharmacist.  
Take time to ask questions – do not feel rushed or under any obligation to make a hasty 
judgement.  
You should clearly understand the risks and benefits of participating in this study so that 
you can make a decision that is right for you and your child/ren – this process is known 
as Informed Consent as per international research requirements.  
 
You are not obliged to take part in this study and failure to participate will have no effect 
on your future care. 
 
You may change your mind at any time (before the start of the study or even after you 
have commenced the study) for whatever reason without having to justify your decision 
and without any negative impact on the care you will continue to receive from your 
pharmacist or the pharmacy staff. 
 
WHY IS THIS STUDY BEING DONE?  
This study is being done because I am conducting research to determine if paracetamol 
preparations are used correctly in children as reflected on the scientific package insert. 
 
WHO IS ORGANISING AND FUNDING THIS STUDY? 
Aadila Patel is the name of the person that is conducting this study in the form of a 
survey. 
Aadila is doing her research for the purposes of attaining a masters degree through the 
University of Western Cape. 
Is paracetamol being prescribed and used at the correct 
therapeutic dose in the children population in South 
Africa? 
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This research is not being funded and is being conducted solely for attaining a master 
qualification. 
 
There will be no remuneration to you for participating in this study. 
 
HOW WILL IT BE CARRIED OUT? 
 
The survey commences in December 2013 and will be completed by the end of 
February 2014. 
 
The survey will be done by collecting responses from 5 pharmacists and 10 caregivers. 
The survey will be conducted at various sites in Cape Town. 
 
The selection of participants will be dependent on their willingness to assist in the 
survey in response to specific set of questions and informed consent. 
 
WHAT WILL HAPPEN TO ME IF I AGREE TO TAKE PART? 
There is no financial compensation to you for taking part in the survey. 
Your input is required to clarify how and when you give your child/ren a paracetamol 
preparation. 
In the case of a pharmacist, the input will be to determine how and when they prescribe 
paracetamol preparations for a child/ren. 
 
It is anticipated that your participation in the research will be 10 minutes. You will 
be required to read this information leaflet, complete the informed consent form 
and completing the survey. 
 
BENEFITS: 
There will be no personal benefit to you in participating in this research. The benefit is 
determining if South Africa is in line with international requirements and practices for the 
use of paracetamol preparations in children. 
 
RISKS: 
There is no risk to you or your child/ren as this survey is being done to gather 
information on the use of the paracetamol product that has been purchased/dispensed. 
 
WHAT IF SOMETHING GOES WRONG AS A RESULT OF MY PARTICIPATION IN 
THIS STUDY? 
There is no chance that anything will go wrong with your participation in this study as 
the data will be analysed to determine how paracetamol preparations is being used. 
 
YOUR RESPONSIBILITIES AS A PARTICIPANT 
Your participation requires that you be honest and do not provide answers that you think 
are correct or answers that you think I should be told. 
Provide your consent in the use of the data that is gathered from the survey. 
 
MY RESPONSIBILITIES TO YOU AS AN INVESTIGATOR 
I will treat you with respect and dignity. To treat all your response in confidence. 
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CONFIDENTIALITY ISSUES 
I will be keeping the data for a period 5 years. 5 years has been chosen to be in line 
with the time that the South African receiver of revenue requires for the retention of 
papers or documentation. 
 
At the end of the 5-year period, the paper copies will be destroyed by means of 
shredding and the electronic copies will be deleted from the hard drives and other 
backups copies that are made. 
 
Please be aware that the data may be used in future research. 
Do you consent to this? Yes/No 
 
 
IF YOU REQUIRE FURTHER INFORMATION 
If you have any further questions about the study, or if you wish to withdraw from the 
study you may do so without justifying your decision and your future treatment will not 
be effected.   
 
For additional information now or any future time, please contact:  
Name: Aadila Patel  Phone No: 0217013594 
 
 
 
 
PROCESS TO DETERMINE VOLUME: MEDICAL DEVICE
1. Images were captured of the various devices in their initial wrapping as purchased from the 
t2. Images were then captured with the medical device being visible next to its packaging, where 
relevant
3. Decision made to use Medi-Rite medicine measure as base measuring device
4. Images of product in each device has been captured
Actual process
5 ml
1. Emptied product into the Medi-Rite unit up to the 5 ml/1 tsp mark
2. Transferred contents into medicine measure
3. When dropper and syringe used, the contents were emptied into the Medi-Rite medicine 
measure4. Unless you are trained to use a syringe, there is no instruction to the positioning of the black 
plunger. For this exercise plunger at bottom tip was used
10 ml
1. Same as 5 ml
2. Investigated devices that could deliver 10 ml in single administration
2,5 ml
1. Same as per 5 ml
2. Investigated devices that could measure 2,5 ml
7,5 ml
1. Same process as 5 ml
2. Investigated devices that could deliver 7,5 ml in a single administration
Tablespoon
1. Contents of 10 ml where emptied from Medi-rite spoon into tablespoon
2. Content remaining was determined.
3. If necessary add product in 5 ml increments until table spoon is full.
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AD CO-MEFENAMIC ACID, (Adco Generics) 
AI Pharm Ltd [P/S] 
Mefenamic acid. 
Indications: 
(SJ) Mild to mod.pain in ac.& chron.condits. includ. 
traumat/arthrit.or musc.ongin. pain. dysmenorrh., 
headache, dent.pain, menorrh. & pyrex. 
IS2) Post-traum.condits.e.g.p81n, swell., inl/amm. for max. 
perof 5 days. 
(SJ) & (S2) SUSP, [P/S] 28/2.7/0220 50 mg/5 mi. 
875643-019 100 ml, R9,37 
875643-027 200 mi. R18,73 
Dosage: Adminwi th meals. for max.7 days. Childr. 6 
mnths-1 yr: 5 mi. 3xdly. 2-4 yrs: 10 ml 3xdly. 5-8 yrs: 
10 mi. 4xdly. 9-12 yrs: 15 ml 4xd!y. 
(SJ) & IS2) CAPS, [P/Sl 28/2.7/0019 
883102-004:250 mg. 18. R10.19 
883102-012:250 mg, 250, R141,47 
Dosage: Admin.3xdly.wi th food for max.7days. Adults: 
1-2 caps. 
Contra-indications: NSA/0 cross-sens, pept. u/c., G/ 
bleed.hist., inflammat.bowel dis., safety in pregn.& lactat. 
not est. , epilept., imp. hepat.funct. 
Side-effects: Gl disturbs.incl.bleed, drowsin., dizz., 
ne!Vousn, vis.d1sturbs., bld.dyscras .. a!lerg. g/omeru!onephrit, 
ac.a/lerg.reacts .. abnorm.ren./ livfunct., bronchoconstrict.in 
asihmat.pts.with aspirsens., platel.funct.aff. 
Special precautions: Poss.enhanc. eff.of anticoags, 
discont. if diarrh./skin rash occurs, monit.ren./livfunct.dur 
prolong. ther, asthma, excl. uterine & other pathology bel. 
prescrib. for menorrlr. 
ADCO-PARACETAMOl, AI Pharm ltd [P/S] 
Paracet. 
Indications: Mild to mod. pain & fe" 
(SO) SYRUP. U/27/11 8 120 mg/5 mi. 
894281-003 100 ml, R6,73 
Dosage: Admin.3-4xdly.as reqd. Max. 4 dos.dly. 
lnfts.3- 12 mnths: 2,5-5 mi. Childr. 1-5 yrs: 5-1 0 mi. 6-12 
yrs: 10-20 ml 
Contra-indications: Sev.livfunct.impairm. 
Side-effects: Pancreatit. , skin/allerg.reacts., blddisords. 
Special precautions: Liv./kidn.dis. 
ADVIl, (Wyeth) Pfizer Consum. [P/S] 
Ibuprofen. 
Indications: Mild to mod.pain, e.g. min.musc. aches & 
strains, headache .. menstr/denf.pain, pain assoc.wth 
migraine. 
(S2) LIQUI-GElS CAPS, 34/27/0193 
892302-005 200 mg, 20, R31 ,81 
Dosage: Admin. with food. 
Adults & childr.over 12 yrs: 1-2 caps.4-6 hrly. Max.6 
caps/24 hrs. 
Contra-indications: Pept.ulcerat./hist, bid. disords., cv· 
dis .. aspir& NSAIO sens., pregn., chi/drund./2 yrs. 
Side-effects: G/ disturbs. inc/. bleed., CNS efts., 
hypersens.reacts.inci.Steven. -Johnson/ tax. epiderm. 
necrolys./ hepatotoxic.& asept.meningit., vis. disturbs., 
bronchosp.in asthmat., cyst1't., haematur, ac.ren. fail .. 
interstit.nephrit .. nephrot. syndr, fluid relent., bld.dyscras., 
revers.irrhibit.of platelet aggregat., photosens., a/veal it., 
pu!mon. eosinophil. , pancreatit.. colit.induct./exacerbat .. 
abnorm.livfunct. test. 
Special precautions: Asthma/bronchosp./bleed disords./ 
CV dis./pept.ulcerat.hist .. anticoag. ther. discont.if vis. 
ANTALGIC, CAPS [P/S] 
Paracet. 
Indications: Fever, mild to mod.pain. 
SF SYRUP, [P/S] X/2 8/64 120 mg/5 mi. 
798983-019 100 ml, R3,86 
Dosage: Dos.may be repeat. 4 hrly.up to 4x/day. 
lnfts. 3- 12 mnths: 2,5 mi. Childr. 1·6 yrs: 5 mi. 7-12 yrs: 
5-1 0 mL 
500 T TABS, [P/S] 27/2.8/0022 
805467-009: 500 mg. 1 000, R65, 19 
805467-017 500 mg. 5 000, R325.31 
Dosage: Adults: 1-2 tabs 4-6 hrly. Max. 8 tabs/ 24 hrs. 
Childr.6-12 yrs: Yz-1 tab 4-6 hrly. Max 4 tabs/24 hrs. 
Chil dr.und.6 yrs: Not recomm. 
I 
Side-effects: Revers. skin rash, blddisords. 
Special precautions: Liver/kidn.dis. 
AUSTEll-PARACETAMOl, Austell [P/S] 
Paracet. 
Indications: Mild to mod. pain & fever 
(SO) TABS. 26/2.8/0406 
713153-001 500 mg, 10, R4,29. 
71 3153-002 500 mg. 20, R8,57 
Dosage: Do not exceed recomm.dos. 
Adults: 1-2 tabs 4-6 hrly. Max.8 tabs./24 hrs. Childr 6-12 
yrs: Yz· l tab 4-6 hrly. Max.4 dos./24 hrs. 
, Contra-indications: Se"livimpairm., safety in pregn. & 
I 
/actat.not est. 
Side-effects: Bld.dyscras., ren.colic./-fail .. hepatit., 
hypersens.reacts.incl.revers.skin rash, 
Special precautions: lmp.kidn./li" funct., exceed. 
; recomm.dos.may cause sev.liv.damage, contact near.med. 
facility 1mmed.in event of suspect. overdos., alcoh.incrliv 
toxic.risk esp.in alcohol. with high dos.& prolong. use. 
Drug interactions: Concom.potent.hepatotox. drugs/ 
drugs induc.livmicrosom.enzyme pass 1ncr toxic.risk. 
metoc/opramide accelert.absorpt., cholestyramine reduc. 
absorpt.if given within 1 hr. probenecid may affect.excret. 
BE-TABS ASPIRIN, Be-Tabs [PiS] j Aspirin 
Indications: Mild to modpain. febrcondits 
(SO) TABS. E/27/104 
798533-005 300 mg. 100. R2 1 ,83 
798533-013 300 mg, 1000, R74,95 
798533-021• 300 mg, 5 000, R358,88 
Dosage: Adults: 1-2 tabs 4 hrly. max.10 days 
Childr.3-4 yrs: \4-Yz tab.4 hrly. 5· 7 yrs: Yz-ll tab.4 hrly. 
7-12 yrs: ll-1 tab.4 hrly 
Contra-indications: Pregn., pept. ulc., haemophil., se" 
ren.impairm., oral anticoag.ther 
Side-effects: Oizz .. gasrrmucosa irrit.& bleed. incl. 
malaena, bld.dyscras., pept.ulc.& ren.papi/1. necros.with 
1 prolong/high dos.use. 
Special precautions: Reye s syndr, asthmat. notable 
sensit .. imp.ren.funct., dyspeps., anaem. , dehydrat. 
Drug interactions: Enhanc. eff.of coumarin anti-coag., 
oral antid1abet.& su!phonam., diminish. elf. of ant1gout 
preps., barbit.& other sedat.may enhanc.toxic.& mask 
resp.sympt.of aspirOO. 
BEDORAL, Be-Tabs [P/S] 
Ketorolac tromethamine. 
Indications: Short-term mod.post-op pain relief 
(S4) INJ, A40/27/0147 
709803-00130 mg/m l, 10x1 ml amps., R147,59 
' Dosage: IV/IM use. Admin.should not exceed. 2 days 
wi th max. IV infus.durat.not exceed. 24 hrs. Admin. low.eff. 
dos. Concom.opiate analges.for furth. pain relief if requir. 
2012-05/ 65 
Ensure adeq.fluid & electro!. ba l. bel. IV infus. Admin. bolus 
dos.over min. 15 sees. 
Sngl.dos.treatm: IM ad min: Admin.slow./deep IM. 
Pts.<65 yrs: One dos.of 10-60 mg.accord.to sev.of pain. 
Pts.;:,65 yrs/mi ld ren. impairm: One dos. of 10-30 mg IV 
ad min: Pts.<65 yrs: One dos. of 10-30 mg. Pts.;:,65 yrs/ 
mild ren. impa irm: One dos.of 10-15 mg. 
Multiple-dos.treatm: (IV or IM). Dos.adjustm. accord.to 
sever.of pain & pt.respons. Max. combin. durat.of multip. 
bolus IM/IV dos.not to exceed Z days. 
Pts.<65 yrs: Max.dly.dos.not.exceed.90 mg IM dos: 
lnit.10-30 mg follow. by 10-30 mg 4-6 hrly.as reqd.upto 
max.dly.dos. IV dos: IV bolus: lnit.1 0-30 mg follow.by 10-
30 mg 6 hrly.as reqd.up to max. dly.dos 
Contin.IV infus: In it: 30 mg follow.by contin. infus. at rate 
of up to 5 mg/hr for up to 24 hrs. up to max. dly.dos. 
Pts.;:,65 yrs/ren. impairm: Max.dly.dos.not to exceed 
60 mg. IM dos: 10-15 mg 4-6 hrly.as reqd. up to max.dly dos. 
IV dos: IV bolus: 10-15 mg 6 hrlyas reqd.up to max. dly. 
dos. Contin. IV infus.not recomm.in th is age group. 
Contra-indications: NSA/0 cross sens., hist./ act. 
pept.ulc./GI bleed, haemorrhag.diathes.incl. coagulat. 
d1sords, full anticoag. the,ncl. prophy/act. low dos. 
heparin, susp./confirm. cerebrovasc. bleed, ops. with high 
risk of haemorrh./ incompl.haemostas .. mod to sevren. 
impairm., pts.at risk of ren.fail.due to vol.deplet. /dehyd.rat., 
pregn.& lactar. safety & efficin childr und.16 yrs.not est., 
prophylact.analges. befsurg , intra-op.use, neuraxial admin., 
concom. oxpentifyll!ne/other NSA/Os. chron.painfcondits 
Side-effects: Hypersens.reacts.inc/.anaphylax., Gil CNS/ 
CV efts., dosdepend.GI bleed./perforat. esp.1n elderly & 
debilit., pancreatit., sweat. . convu/s., thirst. hyperkliJes .. 
asept.mening/1., psychot.reacts., paraesthes., vertigo. 
myalg .. incr urin.freq., oligur. ac.ren.fail., haemo!yt. 
uraem. syndr, flank pain, interstit.nephrit., hyponatraem., 
hyperkalaem., unn.reten t., nephrot. syndr, hyper-/ 
hypotens .. hepatit. , cholestat. Jaund., li" fail., dyspn., 
asthma. pulm. oed., skin reacts.inci.Lyell's & Stevens-
Johnson syndr, purpura, thrombocytopen., post-op wound 
haemorrh., epistax., haematoma, incr bleed.time, abnorm. 
vis. hear loss, tinnit. , oed, weight gain, mj.site reacts., 
lev., asthen., inhib.platel. aggregat .. fluid retent. 
Special precautions: Angioed.hist .. asthma, compf/ 
partsyndr.of nasal polyps, bronchosp., concom. 
methotrexate. , imp.ren.funct., HF, liv dysfunct., concom. 
diuret., kidn.dis.hist., pass. incruter.haemorrh.risk dur. 
labour/deliv, hypovolaem. correct.bef.admin., precipit will 
occur if mix. in small vol. with morphine sulph./ pethidine/ 
promethazine/hydroxyzine HC/, elderly. coagulat.disords .. 
ops. where strict haemostas.is critic.eg.cosmet./day case 
surg., card. decompensat., hypertens. 
Drug interactions: Addit.S/E with other NSAIOs. 
oxpentifylline incrbleed.tendenc, pass. reduc.methotrex. 
clear, incrliplasma cone., plasma conc.incrwith 
salicylate, poss.1ncr ren. impairm. with ACE-inhibit.partic. 
vol.deplet. pts., reduc.diuret.respons. to furosemide. 
BETAGESIC, AI Pharm ltd [P/S] 
Ibuprofen. 
Indications: Pain, muse. -skelet.pain, fever 
(SZ) TABS. U/2.7 /20. 
708186-009 200 mg, 20, R18,58 
Dosage: Adults & childr.over 12 yrs: lnit2 tabs then 
1-2 tabs 4 hrly if necess. Max 6 tabs/24 hrs. 
Contra-indications: Pregn., b/eed.disords .. CV dis .. pept. 
ulcerat./hist.thereof, aspirsens., childr und 12 yrs. 
Side-effects: Oyspeps .. Gl into!.& bleed. nervousn., skin 
rash, prurit., tinnit., oed .. depress. , drowsin. , insomn.. vis. 
disturbs .. hypersens reacts., bld.dyscras, ren.fail 
Special precautions: Coumarin anticoag., revers. ren. 
funct.impairm 
CALPOl, GSK [P/S] 
Paracet. 
Indications: Mild to mod.pain & lev., headache, sore 
throat, toothache, teeth .pains, lev. assoc. with colds & flu. 
PAED.SYRUP. B/27 /767 120 mg/5 mi. 
711 993-009: 100 ml, RZ7,68 
Dosage: Admin. 3-4xdly.at 4 hrly.inteiV. 
3 mnths-1 yr: 2,5 mi. 1-2 yrs: 5 mi. 3-6 yrs: 10 mi. lnfts. 
und.3 mnths: Not recomm 
Side-effects: Revers.skin rash/bld.dyscras. , papill.necros. 
Special precautions: Hepat./ren.dysfunct. 
Drug interferences with laboratory tests and physical incompatibilities common with parenteral solutions have 
not been included. 
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DISPRIN, Reckitt Benckiser [P/S] 
Aspirin. 
Indications: Mild to mod.pain, fever 
(SO} REGULAR STRENGTH TABS, [P/S] B/2.7/570 
720577-004:300 mg, 12, R10,99 
720577-012 300 mg. 24, R19,99 
720577-020 300 mg. 48, R33,99 
720577-039 300 mg, 96, R59.99 
Dosage: Adults: 1-3 tabs 4 hrly if necess. Max. 
12 tabs/24 hrs. Childr: 2-4 yrs: )I tab.max 4xdly. 4-6 yrs: 
!-\-1 tab. max 4xdly. Over 12 yrs 1-2 tabs. Max. 4xdly. Max 
10 tabs/24 hrs. 
(SO) EXTRA STRENGTH TABS, [P/S] M/2.7/292. 
847283-004: 500 mg. 16, R19.99 
720585-015: 500 mg, 24, R29,99 
720585-023 500 mg, 48, R49.99 
Dosage: Adults: 1-2 tabs 4 hrly.i f necess. Max. 8 tabs/24 
hrs. Childr.over 12 yrs: 1 tab 4 hrly if necess. 
(SO} MELTS, [PiS], R/2 8/99 
807206-008: 300 mg, 32, R38,99 
Dosage: Adults: 1-3 tabs 4 hrly if necess. Max. 12 tabs./ 
24 hrs. Chi ldr over 12 yrs: 1-2labs max.4xdly. Max 
10 tabs./24 hrs. 
Contra-indications: Pept.ulc., haemophi/ , sev ren. 
impairm., oral anticoag., 1st & 3rd trimest. pregn. & lactat 
Side-effects: Dizz., Gl·irrit., result.dyspeps., erosion, 
ulcera f., haematemes., melaena, skin erupt., urticar., 
angioed., paroxysm.bronchasp.& dyspn., bld.dyscras.with 
prolong.high dos. 
Special precautions: lncrrisk of gastrirrit. with other 
gastrirritants eg NSAID's, withdr 1 wk.bef surg.because 
ofposs.incrbleed.time, asthma, imp. ren.funct .. dyspeps., 
anaem .• delwdrat. 
Drug interactions: Enhanc.act.of coumarin anticoag. I 
methotrex/oral antidiabet.& sulphonam., dimin. eff.of 
anti-gout preps., barbit.& other sedatenhanc.aspirtoxicity 
& pass mask resp. sympt. 
Warnings: Reye's syndr 
(S2) & (S3} TABS, [P/5] 27 /2 7/0282 
797715-010: 500 mg. 100. R153,48 
Dosage: Admin.for max. 7 days. 
Mild to mod.pain: 500 mg 3xdly. 
Ac.pain: Adults: I nit. 500 mg thereaft. 250 mg 6 hrly. j Childr. Rep. up to 3xd ly. 6 mnths·l yr: 5 mi. 2-4 yrs: 10 mi. 
I 5-8 yrs: 15 mi. 9-12 yrs: 20 mi. Contra-indications: NSA/0 cross-sens .. GIT ulcera f./ 
I inflamm., epilept., imp.hepat.funct. Side-effects: G/ disturbs.incl.haemorrh .. CNS elf.. vis. 1 disturbs .. ac.hypersens.reacts., skin rash, bld dyscras. 
• Special precautions: lmp.ren./liv funct.. elderly with 
dehydrat./ pre-exist.rendis. 
Drug interactions: Eff.of coumaranticoags. enhanc. 
GO-PAIN P, (Gienmark} MDI [P/S] 
1 Paracet . . 
llnd•cat•ons: Mild to mod pam & lev SYRUP, X/2.7/242 895199-009: 120 mg/5 ml, 100 mi. R9.1 7 
I Dosage: Admin.6-8 hrly. Max: 4 dos.dly. lnlts.3-12 mnths: 2,5 mi. Childr: 1-6 yrs: 5- 10 mi. 7-12 
I yrs: 10-20 mi. Side-effects: Skin rash, allerg.reacts., bid dyscras. 
Special precautions: Liv/kidn. dis. 
IBUCINE, (Goldex) Pharm.Contractors [P/S] 
Ibuprofen . 
1 Indications: (S2} When recomm.paed.dos.does not 
I exceed 20 mg/kg 
I 
(S3} lnflamm.joint dis.treatm. 
Mild to mod.pain & inflammat., fev .• musculosket. & joint 
disord.& soft tissdisords. 
, (S2} & (S3} PAED.SUSP, 36/31/0436 I 700315-001 : 100 mg/5 ml, 100 ml, R1 5,71 
I Dosage: Do not admin.to childr.<7 kg/und.1 yr 
I Juvenile rheumat.arthrit: 20 mg/kg dly. in div. dos upto 
. 40 mg/kg/day. 
I Pain: 5 mg/kg bm.with a second dos.aft2 hrs.if necess. 
ECOTRIN, Pharmafrica [P/S] J thereaft.4-6 hrly 
Aspirin. Fov: 5 mg/kg bm.6 hrly. 
Indications: Pain & fe~ Childr.1-2 yrs (7-1 2 kg}: 2.5 ml3-4xdly. 3-7 yrs (14-
(SO) EC TABS, 29/27/0767 23 kg}: 2.5-5 ml 3-4xdly. 8-12 yrs (25-40 kg}: 10 ml 
823481-111 8:81 mg, 50. R32,46 3-4xdly. 
823481-026: 81 mg. 100, R60,04 Contra-indications: Pepwlc., pregn.in J ' trimest .. 
Dosage: 4-B tabs .every 4 hrs.if need. not exceed. 48 . NSAID cross-sens. 
tabs./24hrs. I Side-effects: Gl disturbs.incl.b/eed/pept.ulc., CNS effs .. 
Contra-indications: Haemorrhag.disords .. gout, aspirin hypersens.reacts.inclhepatotox& asept.meningit., vis. 
sens.asthmat., sevrenimpairm., oral anticoag., 1st & 3rd I' disturbs.incl.toxamblyop .. bld.dyscras ..• interstit.ne.phrit., 
trimest.pregn, /actat. nephrot.syndr. renfail.. bronchosp. in asthmat.pts .• cystit., 
Side-effects: Dizz .. G/-irrit./disturbs .. sk1n erupt., anglo· haematur 
oed., rhinit. , paroxysmbronchosp.& dyspn., incrb/eed.time. 1 Special precautions: Pept.ulcera thJst., bleed. d1sords., 
Special precautions: lmp.hepat/ren.funct.. withdr 7 1' asthma. aspir/NSAID's sens., hyppertens., imp.ren/ 
wk.befsurg., asthma, dyspeps .. anaem., dehydrat. card/hepat.funct, bid/ kidn./li~ar eye disord.deve/opm., 
Drug interactions: Enhanc.act.of coumarin anticoag., I elderly, concom. oral anticoags./Li/methotrex.& card. 
sulphonylurea, hypoglycaem.agents, methotrex., glycosides, incrrisk of asept.meningit.in pts. with collagen 
phenytoin, valproic acid, dimin.eff.of anti-gout preps. dis., discont.in case of blurr/dJmin/changes in colour vis. 
Warnings: Reyes syndr ! 
EMPAPED, Nycomed [P/S] 
Paracet. 
Indications: Mild to mod.pain & fever when oral therapy 
not feasible. 
(S2} SUPPS. X/2.7/193, 194. 
819697-001 : 125 mg 10, R38.26 
819700-002: 250 mg, 10, R48,45 
Dosage: Admin.up to 4xdly. 
lnfts. 3-12 mnths: 125 mg. Childr: 1-5 yrs: 250 mg. 
Contra-indications: lmp. kidn/livfunct. 
Side-effects: Skin rash, other allerg.reacts., bid dyscra:S. 
Special precautions: Liv/kidn.d1s. 
FENAMIN, (Aspen Pharmacare: Pharma} 
Pharmacare [P/S] 
Mefenamic acid. 
Indications (S3): Mild to mod.pain from rheumat. , soft 
tiss.injur, painf.musc-.skelet. condits .. dysmenorrh. 
Indications (S2): Post-traumat.condits.(eg.pain, swell.& 
infiamm.) x max 5 days. 
(52} (S3} SUSP, [P/S] 27 /27/0283 50 mg/5 mi. 
797014-004:100 mi. R11,27 
(S2} & (S3} CAPS, [P/S]27/27/0281. 
797707 ·026 250 mg. 250, R 144,78 
1 MYOPRIN, Desatnik [P/S] 
Aspirin. 
Indications: Mild to mod.pain & fev 
EFFERVESC.TABS. 8/2.8/111 7 
845590-001:100 mg, 30. R14,31 
Dosage: Adults: 3-6 tabs 4 hrlyas reqd. Max. 40 tabs/24 hrs. 
Contra-indications: Haemorrhag.disords .. gout, aspirin 
sens.asthmat., 1st & 3rd trimest.of pregn., lac/at 
Side-effects: Dizz .• Gl disturbs .• eros., ulcerat., 
haematemes., melaena, hypersens.reacts.notably 
asthmat .. hypoprothrombinaem., hepatotox partie. in 
I juven.arthrit.& other connect.tiss.disords. I Special precautions: lmp.ren./hepat.funct., discant. 7 wk. bel. sched.surg., Reyes syndr, dyspeps., anaem., dehydrat. I Drug interactions: Enhanc.eff.of coumarin anti-coag. , , dimin.effaf probenecid.& sulphmpyrazone. 
i 
I 
NAPAMOL, AI Pharm Ltd [P/S] 
Paracet 
Indications: Mild to mod.pain, fe~ 
(SO} TABS, [P/S] B/2.7 /1404 
! 745723-136 500 mg. 5 000. R274,71 
I (SO} ELIX, [P/S] B/2.7/1 409 120 mg/5 mi. 
745715-028 100 ml, A10,47 
Dosage: Adults: 1 -2 ta bs 4-6 hrly. Max.8 tabs. dly. 
Childr: Admin. elixir 3-4xdly.as reqd. Max. 4 dos. 
dly. 3-1 2 mnths: 2,5·5 ml 1-5 yrs: 5-10 ml 6-1 2 yrs: 
!-\-1 tab./10 -20 ml 
-3.2 
Contra-indications: Sevlivfunct.impairm. 
Side-effects: Allerg.reacts incl. skin rash. & pancreatit.. 
bid. dyscras. 
Special precautions: Li~/kidn.dis. 
NUROFEN, Reckitt Benckiser [P/S] 
Ibuprofen. 
Indications: Headache & back pain of muscu/o-skelet 
origin, fever, musc.aches & pain, menstrual & den/pain, 
migraine. 
(Sl} TABS, [P/S] S/27/123 
748560-009:200 mg. 12. R15,19 
748560-017: 200 mg. 24, R30,34 
748560-025: 200 mg, 48, R60,63 
748560-033 200 mg. 96, R121.24 
Dosage: Childr.und.12 yrs: Not to be given. 
Adults & childr.over 12 yrs: lnit. 2 tabs. then 1-2 tabs. if 
necess. 4 hrly. Max. 6 tabs./24 hrs. 
Migraine: 2 tabs. 3xdly. 
(Sl} PERIOD PAIN TABS, [P/S] W/27/142 
897984-005: 400 mg, 12. R22,09 
Dosage: 1 200 mg dly in div.dos. Max: 3 tabs/ 24 hrs. Not 
forchildr.und. 12 yrs. 
(S2} CHILDR.SUGAR-FREE SUSP, [P/S] 31/2.7 /0466 
700695-001: 100 mg/5 mi. 100 ml, R28,77 
Dosage: Do not admin.to childr. und.3 mnths. Child r: 
20 mg/kg bm dly in div.dos. Childr.und. 5,6 kg/und.3 
mnths: consult physic. Not to exceed 20 mg/kg bm/day. 
3-6 mnths. (5,6 -7 kg}: 2.5 ml up to 3xdly. 6-12 mnths 
(7-10 kg}: 2,5 ml up to 3xdly. 1·2 yrs (7-12 kg}: 2,5 ml 
up to 3-4xdly. 3-7 yrs (14-23 kg}: 2.5-5 ml up to 3-4xdly 
8-12 yrs (25-40 kg}: 10 ml up to 3-4xdly. For pain a second 
dos.may be giv.aft2 hrs.i f necess.therealt.6 hrly . 
(S2} CHILD.STRAWBERRY SUSP, A40/27/0092 
Indications: Fev/pain & infiammat.assoc with cold & 
flu, sore throat, earache. headache, dent. pain, min.aches 
& sprains. 
712683-001: 100 mg/5 ml, 100 ml, R28,77 
Dosage: Do not admin.to child r.<5,6 kg/und.3 mnths. 
Pain: lnit dos.5 mg/kg bm.a second dos.may be giv. 
aft 2 hrs. if necess.thereaft.6 hrly. 
Fev: lnitdos.5 mg/kg bm.6 hrly. 
Childr: 20 mg/kg bm dly in div.dos. Childrun d. 5,6 kg/ 
und.3 mnths: consult physic. Not to exceed 20 mg/kg bm/ 
day. 3-6 mnths. (5,6 -7 kg}: 2,5 ml up to 3xdly. 6-1 2 mnths 
(7-10 kg ): 2.5 ml up to 3xdly. 1·2 yrs (7-1 2 kg}: 2,5 ml 
up to 3-4xdly. 3-7 yrs (14-23 kg ): 2,5-5 ml up to 3-4xdly 
8-12 yrs (25-40 kg): 10 ml up to 3-4xdly 
Contra-indications: Pept ulc/hist .. bleed disords .. CV 
dis .. aspirsens .. NSA/0 cross-sens., Gl bleed. of perforat. 
relat.ta NSAID's, act.hist.of recurr ulc./haemorrhl 
perforat., HF, childrund3 mnths.{susp}, sevliv& ren funct. 
impairm. , pregn. 1n 3'' trimest. , uncontrasthma 
Side-effects: Gl disturbsincl.bleed/peptulc. activat. , 
CNS efts., hypersens.reacts.incl. hepatotox. & asept. 
meningit., bronchospin asthma pts., cystit., haematur, 
ac. revers.ren.fail., interstit. nephrir. nephrotsyndr. bid. 
dyscras., vis. disturbs. incl.tox.amblyop., photosens., skin 
peel, re vers. platelet aggregat., flu id retent. , a/veolit .. 
pulm. eosinophil., pancreatit.. serskin reacts.inci.Stev. 
John.syndr& toxepiderm.necrolys. 
Special precautions: Asthma. bronchosp., elderly, bleed. 
disords., CV dis. , CHF, hypertens. !Jist, pept.u/cerat.hist. , 
Gl bleed.nsk incrwith incrNSA/0 dos.with ulchist/elderly, 
Gl dis.hist., liv/ ren.impairm., cirrhos, diuret. -induc. vol 
deplet., discont. 1n case of vis. chang., incrasept. meningit. 
risk with collagen dis .. poss.masks sympts. of infect., 
anaem., stomatit. 
Drug interactions: Concom.coumaranticaags/ 
antihypertens/diurets./Li/methotrexa te/aspir& other 
NSA/Ds, incr Gl bleed.& ulcerat.risk with concom. alcoh/ 
corticoster./clopidrogel/ticlopidine/biphosphonates/ 
pentaxyfylline & SSRI's, hypoglycaem. efts. of antidiabet. 
meds.& anticoags. efts.poss.incr. incr.serdigox.conc 
with digox. , Jncwephrotoxic.risk with nephrotox.meds. , 
antihypertens.eff.of antihypertens/diuret. poss. reduc./ 
re vers. , efts. of bone marr depress.incr 
See Also MDR Page 1563 
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Analgesics- 3.2 
PAINAMOL, Be-Tabs [P/S] 
Paracet. 
Indications: Mild to mod.pain & lev. 
(SO) For packs less than 1 DO ml of syrup 
(S1) For packs over 100 ml of syrup 
SYRUP, [P/S] E/27 /1 06 120 mg/5 ml 
752118-021• 50 ml, R4,05 
752118-005 100 mi. R5,36 
752 11 8-011 2,5 L, R75,52 
Dosage: Admin. 3-4xdly. Max.4 dos.dly. 
lnfnts 3 mths.to 1 yr: 2.5 -5 mi. 1-5 yrs: 5-10 mi. 6-12 
yrs: 10-20 mi. 
TABS, [P/S] E/2 7/105 
(SO) For packs less than 25 tablets 
(51) For packs over 25tablets. 
752142-141500 mg 10. R6.27 
752142-001 500 mg. 20. R1 1.40 
7521 42-011• 500 mg. 1 DO. R9 .96 
799629-014 500 mg. 1 ODD. R99.88 
799629-006 500 mg, 5 DOD, R499,34 
Dosage: Adults: 1-2 tabs 4-6 hrly. Max. 8 tabs/ 24 hrs. 
Childr. 6-12 yrs: \1-1 tab 6 hrly. Over 12 yrs: 1 tab 
4-6 hrly. 
Contra-indication: Childr.und.6 yrs . 
Side-effects: Revers. skin rash/bld.disords. 
Special precautions: Liv/ kidn.dis. 
PANADO, AI Pharm Ltd [P/S] 
Paracet. 
Indications: Mild to mod.pain & fever 
(SO) TABS, [P/S] B/2.8/858. 
752274-015 500 mg, 50. R23.17 
752274-066 500 mg, 12, R7,27 
752274-058 500 mg. 24. R10.85 
752274-021 500 mg, 100, R46,36 
Dosage: Admin.3-4 hrly. Not for childr.und.6 yrs. 
Adults: 1-2 tabs. Max. 8 tabs/24 hrs. Childr. 6- 12 yrs: 
Y,-1 tab. Max. 4 doses/24 hrs. 
(SO) MELTABS SUGAR FREE, A39/27/0059 
708438-001• 500 mg. 12. R1 4,31 
Dosage: Dissolv.in mouti]/dispers.in sma ll amnt.water. 
Do not chew 
Adults: 1-2 tabs.4-6 hrly while sympts per.sist. Max.8 
tabs/24 hrs_ 
(SO) CAPS, [P/S] S/2.8/57 
752355-007. 500 mg. 20, R13,15 
Dosage: Admin. 3-4 hrly. 
Adults: 1-2 caps. if reqd. Max.8 caps/24 hrs. Childr.. 9-12 yr.s: 
1 cap. if reqd. Max.4 dos./24 hr.s. 
(SO)INFT.DROPS, [P/S] V/27/209. 
788945-009• 60 mg/0.6 mi. 20 ml, R18.35 
Dosage: I nits. 3 mnths-1 yr: 0.6-1,2 ml4 hr. ly if necess. 
Max. 4 dos./24 hrs. 
(SO) CHILDR.MELTABS, A39/2.7 /0060 
708432-001: 125 mg, 12, R1 2,88 
Dosage: Dissolv.in mouth/dispers.in sma ll amnt. water. 
Do not chew. 
Childr. 1-5 yrs: 1-2 tabs.4 hrly.while sympts. persist. 
Max.4 dos/24 hrs.for max.5 days 
(SO) PAED.SYRUP SUGAR & ALCOHOL FREE, [P/S] 
V/2 8/208. 120 mg/5 ml 
788953-00L 100 ml, R19,81 
(SO) SYRUP, [P/S] B/2.7/1 143 120 mg/5 ml 
752282-026• 50 ml, R1 0,88 
752282-018• 100 mi. R19.81 
Dosage: Admin 6-8 hrly with max. 4 dos/24 hrs. 
lnfts. 3 mnth-1 yr: 2.5-5ml. Childr.. 1-5 yr.s: 5-10ml. 6-12 yrs: 
1()-20 ml 
(SO) PAED.SYRUP STRAWBERRY, 35/2.7/0112. 
120 mg/5 mi. -
703118-001: 50 mi. R10,88 
703118-002100 mi. R1 9,81 
Dosage: Childr.6-12 yrs: 10-20 mi. 1-5 yrs: 5-10 mi. 
lnfts.3 mnths-1 vr• 2.5-5 mi. Repeat dos.4-6 hr.ly if 
necess. Max.4 dos./24hrs. 
Contra-indications: Se" li"funct.impairm., safety in 
pregn.& !actat.not est. 
Side-effects: 8/d.dyscras .• ren.co/ic. ren.fail., sterile 
pyuria. hepatit.. pancreatit., derma tit., skin rash, a/lerg. 
reacts. 
Special precautions: Do not exceed recomm. dos., 
liv.& kidn.dis., alcoh., depend., Me/tabs & ChildrMeltabs: 
Phenylketonurics as contains phenylalanine 
1 Drug interactions: Hepatotox.meds.& enzyme 
I induc.meds.incrhepatotoxrisk, therapeut. effposs 
1 deer by enzyme induc.meds., absorpt. accelerat.by 
I metoclopramide. cholestyramine reduc.absorpt.if gi"en I within! hr , incrrisk of advers.ren.effs.with longterm I sa/icylates. 
PARACET, Be-Tabs [P/S] 
Par.acet. 
Indications: Mild to mod.pain & lev assoc. with colds 
&flu. 
(S1) TABS. 33/27/0203 
1
70471 9-001 500 mg. 1000. R7 1,50 
Dosage: .Not for ch ildr.und.6 yr.s. 
Childr. 6-12 yrs.: l2 to 1 tab.6 hr.ly. Childr.over 12 yrs: 1 I tab 4-6 hrly. Adults: 1-2 tabs 4-6 hr.ly. 
I 
Contra-indications: Se"liv.funct.impairm. 
Side-effects: Sev.liv.funct.impairm.with excess dos., 
pancreatit.. skin rash. other allerg.reacts. bld.disords. 
Special precautions: Liv./kidn.dis., not for use long. 
I than 1 D days. , PERFALGAN, BM Squibb [P/S] 
1
1 
Paracetamol 
Indication: Short term treatm.(not exceed.24 hrs.) of mild 
· to mod.pain, & lev when oral route unsuit. 
(53) SOLFOR INFUS, A38/3.2/0561. 1 g/100 mi. 
7051 03-00L 12x1 00 ml vials. R516,25 • 
Dosage: Admin. as 15 min.infus., Use _orai analges. ther. 
as soon as poss. 
Ad ults & adolesc.weigh.>50 kg: 1 g/admin upto 4x/ 
day. Min.inter.v.betw.each admin.4 hrs. Max. dly. dos• 
4 g. Childr.weigh.>33 kg (approx. 11 yrs) /adults & 
adolesc.weigh. <50 kg: 15 mg/kg (i e 1,5 ml sol./kg) per 
admin. Admin. inter.v.betw.each admin.4 hrs. Max.dly. dos: 
60 mg/kg without exceed.4 g. 
Contra-indications: Sevhepatocel/ul.insuffic., safety & 
efficnot est.in childrweigh.less t11an 33 kg. 
Side-effects: Malaise. hypersens.incl. anaphylax., 
' hypotens., thrombocytopen .. bid. dyscras., ren.co/ic/fail., 
hepatit., pancreatit.. dermatit. 
Special precautions: Ensure no concom.meds. contain 
paracet.to minim.OO risk .. exceed. recomm. dos.may cause 
sevli~damage, hepatocellul. insuffic .• chron.alcoho/_j 
I malnutrit., recov from livdis .. ren.dis .. concom.enzyme-induc. subst., assess.risk vs.benef.in pregn.as experof iV 
I admin.limit., dehydrat. Drug interactions: Probenec.reduc.clear, sa/icy/am. 
I prolong eliminat.ha/1-lile. See Also MDR Pag e 592 
I PERFALGAN PAEDIATRIC, BM Squibb [P/S] Paracetamol 
I Indications: Short term treatm.(not exceed.24 hrs.) of 
mild to modpain & lev. when IV route justif.& when other 
adminroutes not poss.in childr 7 yr & old. 
(S3) SOL. FOR INFUS, A40/3.2/0053 10 mg/ml. 
709807-001500 mg. 12x50 ml vials. R359,10 
Dosage: Use oral analges.ther.as soon as poss. Do not 
exceed recomm.dos. Admin.as 15 min. infus. Sngl.use only. 
Do not mix .with other. meds. 
Childr.l yr & old.up to 33 kg (approx. 11 yrs): 15 mg/kg/ 
admin (ie.1,5 ml sol./kgl upto 4x/day. Min.inter.v.betw.each 
admin.4 hrs. Max.dly.dos• 60 mg/kg. 
Contra-indications: Sevhepatocel/ul.insuffic., chldr 
und.l yr, safety in pregn.& /actat.not demons/rat 
Side-effects: Malaise. hypersens.incl. anaphylax., 
hypotens .. thrombocytopen., bid. dyscras. 
Special precautions: Ensure no concom.meds. contain 
paracet. to minim. 00 risk .. exceed. recomm. dos.may cause 
! se"liv.damage, hepatocellul. insuffic., chron.alcohol./ I malnutrit.. recov. from li"dis., se"ren.insuffic, ren.dis, 
I concom.enzyme-induc.subst., dehydrat. I Drug interactions: Probenec.reduc.c/ear, sa/icy/am. 
1 prolong eliminat.ha/f-/ife. 
1 See Also MDR Page 596 
I 
I' PONAC, (Aspen Pharmacare: Consum) Pharmacare [P/S] Mefenamic acid. 
! Indications (S3): Mild to mod.pain from rheumat.condits., soft 6ss.injur. dysmenonh.& other painf.muscu/oskelet.condits. 1 Indications (S2): Post traumat.condits.such as pain, 
swell., & inflammat. for max.5 days. 
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(52) & (53) SUSP, [P/S] Y/2.7/192. 50 mg/5 mi. 
793264-006: 100 ml, R10,55 
793264-014: 200 mi. R21,10 
(S2) & (S3) FORTE TABS, [P/S] Yi27/158 
794201 -008: 500 mg, 50, R80,94 
(S2) & (S3) CAPS, [PiS] Y/27/157 
796433-003 250 mg, 100, R59,82 
Dosage: Admin.with mea is for. max.x7 days. 
Adults Mild to mod.pai n: 500 mg 3xdly. 
Ac.pain: lnit. 500 mg. thereaft. 250 mg 6 hr.ly. Childr: 
25 mg/kg/bm.dly.in div.dos. May be rep. 3xdly_ 6 mnths. -1 
yr.. 5 mi. 2-4 yrs: 10 mi. 5-8 yrs: 15 mi. 9-12 yrs: 20 mi. 
Contra-indications: Sens.to other NSA/O's with 
prostaglandin synthetase inhibit.activ, Gl u/cerat. I 
inflamm., epilep., imp.hepat.funct., safety in pregn.& 
/acta!. not est. 
Side-effects: G/ disturb.& bleed .. pept.ulcerat., headache. 
drowsin., dizz .• nervousn .. vis. disturb .. hypersens! 
haematol.reacts .. asthma. skin rash 
Special precautions: lmp.hepat./ren. funct., poss.NSA /0 
cross-sens .• avoid in elderly with dehydrat .. pre-exist.ren.dis. 
Drug interactions: May enhanc.coumarin anti-coag eft. 
PONSTAN, (Pharmacia) Pfizer [P/S] 
Mefenamic acid. 
Indications (S3): Mild to mod.pain rn ac.& chron. 
condits .• incl. pain of traumat./arthrit.or muse. origin, prim. 
dysmenorrh .. headache. dent.pain. menorrhag. when due to 
ovulat.dysfunct.bleed .. anti-pyret.in febrile condits. 
Indications (S2): Post-traumat.condits.for a max. 5 days .. 
prim.dysmenorrh.x max.3 days. 
(52) & (S3) CAPS, [P/S] 8{27 /560 
756148-112• 250 mg. 20, R18.30 
Dosage: Gl ir.rit.reduc.if admin.with meals. Max. dural 
7 days. 
Adults: 500 mg 3x/day. 
Menorrhag: 500 mg 3x/day with onset of menstr. flow x5 
days or until cessat.of flow whichever is less. 
Prim.dysmenorrh: 500 mg 3x/day commenc.at onset 
contin.for. max. 3 days while sympts.persist 
(S2) & (S3) FORTE TABS, [P/S] H/27/1 3 
756164-001:500 mg. 50. R86.91 
Dosage: Adults: 500 mg 3xdly. 
(S2) & (S3) SUSP, [P/S] B/2.7/561. 50 mg/5 mi. 
756156-009: 100 ml, R12.31 
756156-017• 200 ml, R24.64 
Dosage: Admin. as necess.upto 3xdly. 
! 6 mnths-1 yr: 5 mi. 2-4 yrs: 10 mi. 5-8 yrs: 15 mi. 9-12 yr.s: 
1
20m! 
(S3) PAED.SUPPS, [P/S] 27 /27/0561 
Indications: Pain & fe"in childr6 mnths-2 yrs. when oral 
thernot pass. 
807435-007:125 mg, 5, R42,1 7 
Dosage: Use for long.than 24 hrs not recomm. 
Childr.6 mnths·2 yrs.weigh.not less than 10 kg: 1 supp. 
reel. 3x/day at 6-8 hr.inter.v. 
Contra-indications: Pept.ulc./intest.ulcerat., imp. 
ren./hepat.funct., other NSA/Os sensitiv, drug indue. 
bronchosp./allerg.rhinit./urticar . chron.GIT inflammat., 
epilep., concom.anticoag. thewnless contin.prothrombin.& 
fact VII/IX & X monit.avail .. safety in pregn.& /actat. 
not est. 
Side-effects: G/ disturbs., hepatit., pancreatit.. pept. 
ulcerat. with/without G/ haemorrh., haemo/yt. anaem., bid. 
dyscras .• anaphylax .• gluc.intol.in diab., hyponatrem., CNS 
efts., vis. disturbs .. convuls .. ear pain, palpitat. , hypotens., 
asthma. bronchosp., dyspn., fac.oed., angioed., laryng. 
oed .. skin & subcutan.tiss.disords.inc/ Ste~-Johns.syndr 
I Lyell 's syndr/erythema multiforme., ren.& urin. disords., 
nephrot.syndr 
Special precautions: Poss.NSA/0 cross-sens .. discont.if 
I diarrh/s.kin rasil expec, monit.bld.counts. & li"funct. with prolong.ther. Gl bleed.poss. without wamsigns. dehydrat .• i ren.dis .. elderly, asthma. pre-ren.condits. /ead.to reduct.in 
t ren.bld. 1/ow/vo /., excl. uter/other pathology befprescrib. I for menorril .. thewot to exceed 7 days 
Drug interactions: Anticoags.effs.enhanc., pass. U toxic. 
PONSTEL AI Ph arm Ltd [P/S] 
Mefenamic acid 
Indications (S3): Mild to mod.pain in ac.& chron. 
condits. include. trauma!., arthrit.or muscui. origin. pain, 
dysmenorrh .. menorrh. & pyrex. 
~i>~~.t~ ~M~.i:1ii. _..i:leal.i:l't'~*1ar.?~ 
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Indications (52): Post traumat.condits.for max. of 5 days. 
(52) & (S3) SUSP, [P/S] 28/2.7/0704 50 mg/5 mi. 
81 0398-0011 00 mi. R12,22 
81 0398-028 200 mi. R24.44 
Dosage: Admin.3xdly.with meals. Not to be cont.for long. 
than 7 days. 
Childr.6 mnths & old: 25 mg/kg bm dly in div.dos or 6 
mnths-1 yr: 5 mi. 2-4 yrs: 10 mi. 5-8 yrs: 15 mi. 9-12 yrs: 
20 mi. May be repeat as necess. up to 3xdly. 
(52) & (53) CAPS, [P/5] 28/27/0703 
812250-001 250 mg. 20. R18.16 
812250-036 250 mg. 250, R227.01 . 
(S2) & (SJ) FORTE TABS, [P/S] 28/2.7 /0548 
810371-006 500 mg, 50, R86,20 
Dosage: Adults: 500 mg 3xd ly.with meals. 
Menorrh: 500 mg 3x/day with onset of menstr. flow x 
5 days or unt.flow cessat.whichev.is less. 
Prim.dysmenorrh: 500 mg 3x/day commenc.at pain onset 
cohtin .for max.3 days whi le sympt. persist 
Contra-indications: NSAID cross-sans .. inflammat 
bowel dis., peptulc./ rntest.ulcerat. hist., imp.ren./hepat. 
funct .. epilept, safety in pregn.& lactat.not est. 
Side-effects: Gl disturbs .inc/. bfeed./ulcerat./ chofestat. 
jaund.! hepatit., CNS ells .. convufs., vis. disturbs., ear 
pain. hypotens .. asthma, pafpits .. dyspn., haemofyt. 
anaem .• bld.dyscras. incl. bone manap/as .. ac.hypersens. 
reacts .• oed. esp.faryng., Stevens-Johnson syndr, Lyell's 
syndr, perspirat., extol/ derma tit., renfail., afferg 
gfomerufonephrit .• papil/.haematur, dysur, hyponatraem., 
ac.interstit.nephrit., nephrot.syndr 
Special precautions: Excf.uter/other pathology bef 
prescrib. for menorrh .. discont.in case of diarrh./ skin rash. 
reguf.bfd.counts /LFT advis. dur fong t. ther, elderly & 
debifit, gfuc.intol.in diab .. dehydrat. ren.dis., asthmat.pts. 
with aspi'"ens .. HF li"dysfunct .. concom.diurets/Li. 
Drug interactions: Anticoag.profong.prothromb. time, 
pass. toxic.with Li. 
PROLIEF, AI Ph arm ltd [P/S] 
Paracet. 
Indications: Mild to mod.pain, lev 
(SO) TABS. B/2.7/1259 
757403-1 07: 500 mg. 5 000, R288,61 
757403-113: 500 mg. 20 000, Rl 154.44 
Dosage: Admin 4 hrly when necess. 
Adults: 1-2 tabs. Max. 8 tabs/24 hrs. Childr. 6-12 yrs: 
h -1 tab. Max. 4 tabs/24 hrs. 
Contra-indications: Se" li"funct.impairm .. chifdr und.6 
yrs.not recomm. 
Side-effects: Revers.skin rash/bld disords. 
Special precautions: Liv./kidn.dis. 
RAYZON, Pfizer 
See Section 4.1.3. 
TORA-DDL, (Akacia) Roche [P/S] 
Ketorolac tromethamine. 
Indications: Short-term mod.post-op pain relief 
(S4)1NJ, [P/5] 28/27/0570, 0571 
819344-028: 10 mg/ml, 5xl ml amps., R85.77 
819352-012:30 mg/ml. 5x1 ml amps, R145,97 
Dosage: IV/IM use. Admin.should not exceed. 2 days 
wi th max. IV infus.durat.not exceed . 24 hrs. Adm in.low. elf. 
dos. Concom. opiate ana lges.for furth. pain re lief if requir. 
Dly.morphine dos. equir. is less ti}an norm.requir.follow. 
major surg if used in assoc.with Tora-Ool. Ensure adeq. 
fluid & electro !. bal.bef IV infus. Admrn .bolus dos.over 
min. 15 sees. 
Sngl.dos.treatm: IM admin : Admin.slow./deep IM. 
Pts.<65 yrs: One dos.of 10-60 mg.accord.to sev.of pain. 
Pts.;,65 yrs/mild ren.impairm: One dos. of 10-30 mg. IV 
ad min: Pts.<65 yrs: One dos. of 10-30 mg . Pts.;,65 yrs/ 
mild ren . impairm: One dos.of 10-15 mg. 
Multiple-dos.treatm: (IV or IM). Oos.adjustm. accord. to 
sever.of pa in & pt.respons . Max. comb in. durat.of multip. 
bolus IM/IV dos.not to exceed 2 days. Pts.<65 yrs: Max. 
dly.dos.not. exceed.90 mg. IM dos: lnit.1 0-30 mg follow. 
by I 0-30 mg 4-6 hrly.as reqd.upto max.dly.dos. IV dos: IV 
bolus: lnit. 10-30 mg follow.by 10-30 mg 6 hrly.as reqd. 
up to max.dly.dos. Contin.IV infus: \nit: 30 mg fo llow.by 
contin. infus.at rate of up to 5 mg/hr for up to 24 hrs. up to 
max.dly.dos. Pts.;,_65 yrs/ren.impairm: Max.dlydos.not 
to exceed 60 mg. IM dos: 10-15 mg 4-6 hrly.as reqd. up to 
1 max.dly dos. IV dos: IV bolus : 10-15 mg 6 hrly. as reqd. 
, up to max. dly.dos. Contin.IV infu s. not recomm.in this age 
group as limit.exper. 
(54) TABS, [P/5] 28/27/0572 
819336-017 I 0 mg. I 00. R646,97 
Dosage: Short term use on ly for up to 5 days. When 
transf.from inj., tot.combin.d ly.dos .of all forms of ketorolac 
on day of transit.should not exceed 90 mg for pts.s65 yrs.& 
60 mg for prs.>65 yrs .. ren .impair pts.& pts.weigh.less 
than 50 kg. Tot. oral dos.should not exceed 40 mg on the 
day change is made. 
Sngl.dos: One dos.of 10 mg 
Multip.dos: Recomm.1 tab.4-6 hrly as requir with 
max.40 mg/day. 
Contra-indications: Hist./ act. pept.ulc./GI bleed./ 
perforat.. full anticoag.thermcf. prophyfact. low dos.heparin, 
haemorrhag. diathesincl. coagulat.disonds., NSA/Dcross 
sens. susp./confirm.cerebrovasc.bleed., aps with high risk 
afhaemorrh./incampl.haemostas. , mod. to sevren. impainn., 
pts.at risk of ren.faif.due to val. deplet/dehydrat., durpregn./ 
labourjdeliv /facta I., safety & effic.rn childwnd.16 yrs.not 
est., prophylact.analges.befsurg., intra-op.use. neuraxiaf 
admrn .. concomoxpentifyffine/other NSA/Os/ chron.painf 
' condits., high haemorrh risk surg./rncompf.haemostas. 
Side-effects: Hypersens.reacts.incf.anaphylax., Gl diSturbs. 
incl.fulln./rect.b/eed./stomatit./ pancreatit.. dosdepend. 
Gl bleed./perforat.esp.in elderly & debilit. sweat., excess. 
thirst. CNS elf, dizzin .• headache, pareasthes., convuls., 
I 
vertigo, myafg., hyperkines., asept.meningit., psycho!. 
reacts. mcwnn freq. olrguc, ac ren tart.. hyponatraem, 
hyperkalaem , haemolyt. uraem syndr. flank pam mterstrt. 
nephnt, unn re lent, nephrot syndr. flush bradycard, 
I 
pallor. hyper-/hypotens, pafp1tat , chest pam, hepatrt, 
cho/estat Jaund lwfarf, dyspn. asthma, pulm oed, skrn 
reacts mel Lyell's & Stevens-Johnson syndr/exfollratrve 
derma tit, purpura, thrombocyt.open, past op wound 
haemorrh, eprstax, haematoma, mer bleed trme. abnorm 
taste/Vis . hear loss, tinnit.. asthen.. oed., werght gain, ini 
site reacts .• fe•. inlrib.platel. aggregat., prolongs bleed. time, 
fluid retent. , poss/aryng./ angio-oed.with/without aspic 
hypersens .• serGI tOXIC. with/without pre"sympt. 
Special precautions: Pass. incwterhaemorrh. risk dur 
'
labour/deli" . precipit. will occur if mix. in small val. with 
morphine sufph./ pethidine/ promethazine /hydroxyzine 
HCI, hypovo/aem. correct.befadmin., elderly, imp.ren. 
, tuner., kidn. dis. hist., ops.where strict haemostas.is critic. 
eg cosmet./day case surg., card.decompensat.. hypertens .. 
concommethotrexate, discont.therif S&S of li"dis.devel., 
angroed.hist., asthma, campi./ part.syndrof nasal polyps, 
branchosp., consid.opioid S/E when used concom.esp.dur 
I 
day surg., HF, fiv dysfunct., concom.diuret., bleed. risk. 
Drug interactions: Addit.S/E with other NSA/Ds, 
oxpentifylline incr.bleed. tendenc, a/tarat. in 
pharmacokinet. with probenicid, pass. reduc.methotrex. 
clear , incrLip/asma cone., reduc. diuret.respons. to 
furosemide, poss.ina ren. impairm. with ACE-inlribit.partic. 
vof. depfet. pts 
VARIPAN, (Specpharm) LeBasi [P/S] 
Paracet. 
Indications: Mild to mod.pain, fev. 
(SO) TABS, 33/27/0435 
7011 40-003 500 mg, 20. R8,39 
Dosage: Adults: 1-2 tabs.4-6 hrly. Max.8 tabs/24 hrs. 
Childr.6-12 yrs: 0 -1 tab. 6-8 hr ly. Max.4 dos. I 24 hrs. 
Contra-indications: Sev.livfunct.impairm., childrund.6 
yrs.not recomm. 
Side-effects: Pancreatit., skin rash. allerg.reacts., bid. 
dyscras. 
Special precautions: lmp.kidn./li"funct. 
Drug interactions: Absorpt. acce/erat.by metocfopramide, 
' probenecid alters plasma cone. 
VIBURCDL, Heel [P/S] 
Chamomilla 01 I, I mg. belladonna 02 1,1 mg, dulcamara 
04 1,1 mg. plantago major 03 1, I mg. pulsatilla 02 2,2 mg, 
I calcium carbonicum hahnemanni DB 4.4 mg. 
!
Indications: Restless. wrth/without fever in infts.& childr 
SUPPS. U5677. 
812943-007 12, R92.15 
' Dosage: Ac.condit: I suppos. to be rep .on sev. occasions. 
Alt.alleviat.insert 1 suppos. 2-3xdly. I nits. up to 6 mnths: 
Max.1 suppos.2xdly. 
Analgesics- 3.2 I 3.3 
WOODWARD'S PARACETAMDL, (Aspen Pharmacare: 
Consum.) Pharmacare [P/S] 
Pa1acet. 
Indications: Mild to mod.pain & lev. 
(SO) ALCOHOL & SUGAR FREE SYRUP, X/27/207 
726176-001 : 120 mg/5 mi. 100 ml, R19,1 5 
Dosage: Rep. 4-6 hrl y. if necess. Max. 4 dos./day. 
I nits. 3-1 2 mnths: 2,5 mi. 1-4 yrs: 2,5-5 mi. 5-8 yrs: 
5-10 mi. 9-12 yrs: 10-15 mi. 
Contra-indications: Sev fivfunct. rmpairm. 
Side-effects: Skin ras/1, bfd.disords. 
Special precautions: lmp.ren./li"funct. 
XEFO, Nycomed [P/S] 
Lornoxicam 
Indications: Short term treatm.of mild to mad. pain when 
oral admin.inappropr 
(S3) 1NJ, 33/31/0249. 
860670-007 8 mg/vial. 5 vials. Rl25,53 
Dosage: Admin IV/ IM 
Admin.in 8 mg dos. Dly.dos.not exceed.16 mg. A further 8 
mg within 1• 24 hrs.could be need. 
(53) TABS, 33/31/0247,0248. 
Indications Short term treatm.of mild to mod. pain assoc. 
with extra artic.inflamm. symptomat. treatm.of pain & 
inllammat.in osteoarthrit.& rheumat.arthrit. 
860654-001: 4 mg, 20, R67,35 
860662-004 8 mg. 20. R96,06 
860662-012 8 mg. 100, R480,28 
Dosage: Admin.bef.mea Is. lndividualise. 
Pain: 8-16 mg/day in 2-3 div.dos. Max.tot.d ly. dos.16 mg. 
Contra-indications: Prev.hypersens.reacts. to other 
NSAID meds.incf.acetyl.salicyf. acid., Gil cerebra vase. 
bleed., bleed. & coagulat.disords .. act. pept.ulcerat./ 
hist.of recun pept. ulcerat., se"li"/ren.impairm., 
thrombocytopen, se"/ uncontro/.card.fail., elderly 
(>65 yrs). pregn.& factat .. childrund.18 yrs., Ta bs also: 
elderly (>65 yrs) & wergh. < 50 kg & for ac. surg. , lnj also: 
hypovolaem./dehydrat. 
Side-effects: Lac. reacts .. CNS efts., sweat., oed., afferg. 
reacts., vis.disords., Gf drsturbs.incf. pept. u/cerat. with I 
without bleed.. haemorrhord./ rect. bleed., bld.dyscras .. 
muscu/o-skelet.disords., migraine. paraesthes., taste 
penvers .. tinnit.& tram .. rasp.& skin disords., micturit 
disords. pafpitat., tach yea rd., chngs.in BP 
Special precautions: Drscont.therapy with appropr 
therapeut.act.if G/ ulcerat./bleed. develops, prev 
cerebrovasc.haemorrh., SLE, u/c. co/it .. Grahn's dis., 
porphyr., haematopoiet. disords .. reduc.card. funct., hepa t. 
dis., coagu/at. disords., treatm.fong. than 3 mnths., elderly 
(>65yrs.}, imp.ren.funct., monit.ren.funct.in pts.for maj.surg./ 
comprom.ren.funct./CF!concom. diuret./ nephrotox meds. 
Drug interactions: Poss.prafang.bleed.time with concom. 
anticoagul./platef.aggregat.inhib .. pass. incr hypogfcaem. 
eff. with sufphonyfureas .. incr risk of S/E with other NSA/0 
& aspr, deer effie. at loop diuretdrugs .. decr.eff.of ACE 
inhib.& risk of ac. ren. insuff., incrLi peak cone., high dos. 
methotrexate. high. plasma cone. with cimetidine, deer 
renc/earance of digoxin. incrren. toxic. with cycfosporin, 
CYP2C9 indue.& inhibit. 
See Also MOR Page 1388 
3.3. Combinations 
ABFLEX-4, (Cipla Medpro) First Pharm [P/S] 
Paracet.450 mg, doxy lam ine succin .5 mg, calf. 30 mg, cod. 
phosph.1 0 mg. 
Indications: Mild to mod.pain assoc. with tens. 
(52) TABS, 28/2 8/0383 
826766-022 20, R8.49 
826766-013 100, R42.45 
826766-023 I 000, R424,51 
Dosage: Adults & childr.l2 yrs.& old: 2 tabs 4 hrly as 
necess. Max.B tabs./day. 
Contra-indications: Resp.depress.esp.in pres. of cyanosis 
& excess.bronch.secret., aft.bil.tract. ops., ac.alcohol., 
head injur& condir.in which IC-press.rais., branch. asthma 
attack, HF second. to chron. lung dis .. MAO/, sa fety in 
pregn.& factat.not est. 
Side-effects: Skin rash incl.prurit./urticar., alferg. reacts., 
bld.disords .. resp.depress .• bradycard., circufat.faif .. 
eRELOX'ti 
cefpodoxime 
- --- · ·-- ----··- ·-
 
 
 
 
  
 
 
  
 
 
  
 
 
1 of 3
No Medical Device Order of 
product
Contents (all?) Contents 
remaining
Observations Cleaning of device
1 Medi-Rite 
Medicine spoon
1 n/a n/a 1) Pouring the product into the medicine spoon 
can only be done in one way because of the 
scoop shape
2) During pouring, the grading marks are not 
visible to the individual therefore making it 
difficulty to ensure that the correct volume id 
being poured.
3) Pouring from device into a mouth (at lips) is 
impracticable as there is much spillage due to 
the device design having an upward shape.
4) However if the device is placed halfway into 
the mouth there is no spillage. This latter was 
performed by the researcher and not on a child 
younger than 18 years
1) As per house hold 
item
2) No special 
requirements
2 Medicine 
measure 5 ml
2 All emptied with no 
wastage
none 1) It is easy to empty the product from the Medi-
rite spoon
Medicine 
measure 2,5 ml
14 All contents were 
emptied
none As per 5 ml
3 Dis-chem Super 
Dropper
5 From dropper to Medi-
Rite
(4,5 ml to 3/4 tsp 
[3,75 ml])
under by 1/4 
tsp
1) Instruction to rinse device after each use 
noted on the actual device.
2) In drawing up the product, the vacuum 
suction provided by the flexible rubber gave a 
maximum of 4,5 ml reading after several 
attempts.
3) Volume obtained varied from 3/4 tsp (3,75 
ml) to 4,5 ml. It was not possible to get to 5 ml 
in one draw.
4) Repeat with water only draw between 4,5 ml 
and 5 ml
1) Rubber stopper can 
be removed
2) However practicality 
after use has not been 
evaluated; that is will 
the rubber continue to 
provide adequate 
suction to deliver dose
Product used: Adco Napamol elixir
MEDICAL DEVICE DELIVERY VOLUME *
 
 
 
 
2 of 3
No Medical Device Order of 
product
Contents (all?) Contents 
remaining
Observations Cleaning of device
16 All contents were 
emptied
Just under 
2,5 tsp
1) Had to reduce to 2,5 ml in volume by gentle 
pressure on the rubber tubing
4 Syringe 5 ml 
(SurgiPlus)
6 All emptied no 
wastage
Just over 5 
ml
1) Drawing up contents from a bottle into 
syringe is not practical. The bottle was full 
during this experiment but not once the bottle 
is 3/4 full.
2) Volume is similar to Medi-Rite volume
3) Syringe does not reach all the way to the 
bottom of the bottle
1) Plunger can be 
removed and device 
cleaned
2) No special 
precautions
17 All contents were 
emptied
2,5 ml The is correlation between the two devices
5 Syringe 5 ml 
(Pharmacist 
Choice)
7 All emptied no 
wastage
Just over 5 
ml
Same comments as SurgiPlus 1) Plunger can be 
removed and device 
cleaned
2) No special 
precautions
n/a n/a Grading is marked in increments of 0,2 ml 
therefore not possible to measure 2, 5 ml
6 Teaspoon A 3 and 8 There was spillage of 
some of the contents.
REPEAT: 
1st: n/a
Repeat: 1/2 
tsp (2,5 ml)
1) Contents were spilled as a result of the 
teaspoon being at an angle. Initially the volume 
spilt was not measured.
2) However in the repeat to obtain volume, only 
2,5 ml available in the teaspoon.
1) Is a house hold item 
2) No special 
requirements
7 Teaspoon B 4 Not all contents (5 
ml) were able to full 
the tsp
Just under 1 
ml
Contents were poured/emptied from the Medi-
Rite device into Tsp B very slow to ensure no 
spillage. The reminder of the contents in Medi-
Rite was evaluated.
1) Is a house hold item
2) No special 
requirements
 
 
 
 
3 of 3
No Medical Device Order of 
product
Contents (all?) Contents 
remaining
Observations Cleaning of device
8 Dis-chem Med 
Dropper (3 ml)
9 1,5 ml 1 ml; loss of 
0,5 ml
1) Repeated attempts only resulted in a 
maximum of 1,5 ml
2) Other comments as the 5 ml dropper are 
applicable
1) Practicality after use 
has not been evaluated; 
that is will the rubber 
continue to provide 
adequate suction to 
deliver dose
15 n/a n/a It was not possible to obtain 2,5 ml
9 Medicine 
dropper 
(FirstAid) 
11 Cannot be measured 1) Product was not contained 
2) Contents or product leaked from the 
opening from the onset
3) Volume was under 1 ml mark; appeared to 
be halfway thus estimate is 0,5 ml
1) Stopper can be 
removed
2) Dropper is glass so 
care needs to be 
exercised during 
cleaning
10 Syringe 3 ml 10 & 13 All emptied no 
wastage
Just under 3 
ml mark
1) The fill was just under 3 ml
2) Based on the result of the 10 ml as well, a 
repeat of the volume was performed
3) The results were still the same
1) Plunger can be 
removed and device 
cleaned
2) No special 
precautions
Grading is in 0,2 ml increments therefore not 
possible to draw 2,5 ml
11 Syringe 10 ml 12 All contents were 
emptied
Just over the 
10 ml mark
1) The syringe just fitted into the mouth of the 
product bottle
2) Same comments as SurgiPlus
Plunger can be 
removed and device 
cleaned
No special precautions
18 All contents were 
emptied
2,5 ml 2,5 ml: Contents of both devices yield the 
same volume
19 All contents were 
emptied
8 ml 7,5 ml: Contents was over by 0,5 ml in the 
Medi-Rite container
12 Tablespoon 20 All contents were 
emptied
10 ml Contents were transferred form the medicine 
measure into the tablespoon.
Volume delivered is 10 ml
1) Is a house hold item
2) No special 
requirements
* Devices will be kept until thesis has been finalised
 
 
 
 
Package insert source summary: 
 
No. Proprietary name Procurement 
site 
Advice Date of 
publication 
Formulation 
details 
Dosage; 
comparison 
PIL PIL: Other 
1 Adco-Paracetamol Syrup SAEPI n/a 23 August 
1989 
Alcohol  n/a no n/a 
2 Antalgic SF syrup        
3 Antalgic 500 T Tablets        
4 Austell-Paracetamol tablets        
5 Calpol Paediatric Syrup Vitacare n/a April 2011 Sucrose and 
alcohol free 
n/a no n/a 
6 Empaped (Suppository) Vitacare n/a Not available no n/a no n/a 
7 Go-Pain P (syrup) SAEPI n/a April 1996  Alcohol no n/a 
8 Napamol Tablets SAEPI n/a 15 April 1991 no n/a no n/a 
9 Napamol elixir (Adco Napamol 
Elixir) 
Dischem n/a 15 April 1991 No - no n/a 
10 Painamol Syrup Industry n/a Not available no no no n/a 
11 Painamol Tablets Personal n/a 19 June 1974 Sugar content Product 
examination 
does reveal 
breakline 
no n/a 
 
 
 
 
No. Proprietary name Procurement 
site 
Advice Date of 
publication 
Formulation 
details 
Dosage; 
comparison 
PIL PIL: Other 
12 Panado Tablets PicknPay 
Family  
None; off the 
shelf purchase 
27 June 2005 Sugar free Product 
description: 
Has 
breakline/sco
red 
no n/a 
13 Panado Meltabs Sugar free Vitacare n/a 10 March 2005 Sugar free n/a No n/a 
14 Panado Capsules PicknPay 
Family  
None; off the 
shelf purchase 
August 1984 Sugar free  Coincide on 
pack and 
MIMS; pack 
& PI reflect 
not for 
children 
under 9 
years 
No n/a 
15 Panado Infant Drops Vitacare n/a August 1990 Sugar free n/a no n/a 
16 Panado Children Meltabs Dischem None; off the 
shelf 
10 March 2005 Sugar Free As per MIS; 
Carton & PI 
differ: 5/10 
days 
no  
17 Panado Paediatric Syrup Sugar 
and alcohol free 
Vitacare n/a 23 June 2006 Alcohol, sugar 
and tartrazine 
free 
n/a no n/a 
18 Panado Syrup (Panado Paediatric 
Syrup?) 
   Sugar and 
tartrazine free 
   
19 Panado Paediatric Syrup 
Strawberry 
Vitacare n/a 26 March 2002 Alcohol and 
sugar free 
n/a no n/a 
 
 
 
 
No. Proprietary name Procurement 
site 
Advice Date of 
publication 
Formulation 
details 
Dosage; 
comparison 
PIL PIL: Other 
20 Panado Effervescent Dischem None, off the 
shelf 
23 July 1992 Sugar Free Physical 
examination 
reveals that 
eh tablet 
does not 
have a 
breakline; 
how can the 
tablet be 
broken in ½ 
as per dose 
instruction in 
the PI? 
no n/a 
21 Paracet Tablets        
22 Perfalgan Solution for infusion MDR 2012 n/a Not listed n/a n/a no n/a 
23 Perfalgan paediatric Solution for 
infusion 
MDR 2012 n/a Not listed n/a n/a no n/a 
24 Prolief Tablets        
25 Varipan tablets        
26 Grand-Pa Paracetamol tablets PicknPay 
Family 
None; off the 
shelf purchase 
23 July 2010 Sodium 
bicarbonate 
(630 mg) 
reflected as 
active 
Sugar free 
Coincides to 
pack  
23 July 
2010; only 
paracetamo
l as active 
Children 
over 12 
specified 
under 
special 
care and 
‘how to 
take’ 
section 
 
 
 
 
 
 
 
Summary of DOSING INFORMATION of paracetamol containing products 
South Africa 
 
The following is a list of products1  reflected in MIMS2 3May 2012. The list is specific to 
products aimed at dosage delivery to children aged 0 to 18 years4 containing 
paracetamol as a single5 ingredient 
 
ORAL 
 
LIQUIDS: N = 11 
 
Form Strength – 
paracetamol 
per dosage 
unit 
Age Dosage 
(paracetamol 
quantity) 
Frequency Maximum daily 
dose 
Preparations 
Liquid 120 mg per 
5 ml 
3 – 12 
months 
2,5 ml - 5 ml 
(60 mg – 120 
mg) 
3- 4 times 
daily 
(6- 8 hourly) 
Four doses 
(480 mg) 
1. Adco-
Paracetamol 
Syrup 
2. Napamol elixir 
(Adco-Napamol 
elixir) 
3. Painamol Syrup 
4. Panado 
Paediatric Syrup 
Sugar and 
alcohol free 
5. Panado Syrup 
1- 5 years 5 -  10  ml 
(120 mg – 240 
mg) 
3- 4 times 
daily 
(6- 8 hourly) 
Four doses 
(960 mg) 
6 – 12 years 10 – 20 ml 
(240 mg- 480 
mg) 
3- 4 times 
daily 
(6- 8 hourly) 
Four doses 
(1 920 mg) 
12- 18 years Not listed Not listed Not 
applicable 
Difference Under 3 
months 
10 mg/kg 4 hourly Four doses 
not longer 
than 5 days 
(no quantity 
listed) 
1. Panado 
Paediatric Syrup 
Sugar and 
alcohol free 
                                                          
1 Pharmacological classification: Analgesic (3), Analgesics and antipyretics (3.2) 
2 Listing is based on fee; hence not all registered products will be reflected 
3 Monthly publication that has abbreviated product labelling information 
4 As per definition in the National Health Act 
5 Multicomponent preparation are not a component of this review 
 
 
 
 
Form Strength – 
paracetamol 
per dosage 
unit 
Age Dosage 
(paracetamol 
quantity) 
Frequency Maximum daily 
dose 
Preparations 
Liquid 120 mg per 
5 ml 
Under 3 
months 
Not 
recommended 
Not 
applicable 
Not 
applicable 
1. Calpol Paediatric 
Syrup 
3 – 12 
months  
2,5 ml at four 
hourly 
intervals 
(60 mg) 
3- 4 times 
daily 
(6 – 8 hourly) 
Not listed 
1 – 2 years 5 ml at four 
hourly 
intervals 
(120 mg 
3 – 4 times 
daily 
(6 – 8 hourly) 
Not listed 
3 – 6 years 10 ml at four 
hourly 
intervals 
(240 mg) 
3 – 4 times 
daily 
(6 – 8 hourly) 
Not listed 
6 – 12 years Not listed Not listed Not 
applicable 
12- 18 years Not listed Not listed Not 
applicable 
Liquid 120 mg per 
5 ml 
3 – 12 
months 
2,5 ml – 5 ml 
(60 mg – 120 
mg) 
4 – 6 hourly 
(4- 6 times) 
Four doses 
in 24 hours 
(480 mg) 
1. Panado 
Paediatric Syrup 
Strawberry 
 1 - 5 years 5 ml – 10 ml 
(120 mg – 240 
mg) 
4 – 6 hourly 
(4- 6 times) 
Four doses 
in 24 hours 
(960 mg) 
 6 – 12  years 10 ml – 20 ml 
(240 mg – 480 
mg) 
4 – 6 hourly 
(4- 6 times) 
Four doses 
in 24 hours 
(1 920 mg) 
 12 – 18 
years 
Not listed Not 
applicable 
Not 
applicable 
Liquid 120 mg per 
5 ml 
3 – 12 
months 
2,5 ml 
(60 mg) 
6 - 8 hourly Four doses 
(240 mg) 
1. Go-Pain (syrup) 
1- 6 years 5 – 10 ml 
(120 mg – 240 
mg) 
6 – 8 hourly Four doses 
(960 mg) 
7 – 12 years 10 - 20 ml 
(240 – 480 
mg) 
6 – 8 hourly Four doses 
(1 920 mg) 
12 – 18 
years 
Not listed Not 
applicable 
Not 
applicable 
 
 
 
 
Form Strength – 
paracetamol 
per dosage 
unit 
Age Dosage 
(paracetamol 
quantity) 
Frequency Maximum daily 
dose 
Preparations 
Liquid 120 mg per 
5 ml 
3 – 12 
months 
2,5 ml  
(60 mg) 
4 hourly 
(6 times) 
Four doses 
(240 mg) 
1. Antalgesic Syrup 
1- 6 years 5 ml 
(120 mg) 
4 hourly 
(6 times) 
Four doses 
(480 mg) 
7 – 12 years 5 – 10 ml 
(120 mg- 240 
mg) 
4 hourly 
(6 times) 
Four doses 
(960 mg) 
12- 18 years Not listed Not listed Not 
applicable 
Liquid 120 mg per 
5 ml 
3 – 12 
months 
2,5 ml 
(60 mg) 
3- 4 times 
daily 
(6 – 8 hourly) 
Four doses 
per day 
(240 mg) 
1. Woodward’s 
Paracetamol 
Syrup 
1 – 4 years 2,5 – 5 ml 
(60 – 120 mg) 
3- 4 times 
daily 
(6 – 8 hourly) 
Four doses 
per day 
(480 mg) 
5- 8 years 5 – 10 ml 
(120 – 240 
mg) 
3- 4 times 
daily 
(6 – 8 hourly) 
Four doses 
per day 
(960 mg) 
9 – 12 years 10 - 15 ml 
(240 – 360 
mg) 
3- 4 times 
daily 
(6 – 8 hourly) 
Four doses 
per day 
(1 440 mg) 
12 – 18 
years 
Not listed Not listed Not 
applicable 
Liquid 60 mg per 
0,6 ml 
3 – 12 
months 
0,6 ml – 1,2 ml 
(60 mg – 120 
mg) 
4 hours 
(6 times) 
Four doses 
in 24 hours 
(480 mg) 
1. Panado Infant 
Drops 
 
 
 
 
 
 
TABLETS: N = 13 (11 + 1 =1) 
Form Strength – 
paracetamol 
per dosage 
unit 
Age Dosage 
(paracetamol 
quantity) 
Frequency Maximum daily 
dose 
Preparations 
Tablet 500 mg per 
tablet 
Children 
under 6 
Not 
recommended 
Not 
applicable 
Not 
applicable 
1. Antalgesic 500 T 
Tablets 
2. Austell-
Paracetamol 
tablets 
3. Painamol tablets 
4. Napamol tablets 
6 – 12 years ½ - 1 tablet 
(250 – 500 
mg) 
4- 6 hourly 
(4 – 6 times) 
4 tablets in 
24 hours 
(2 g) 
12 – 18 
years 
Not listed Not 
applicable 
Not 
applicable 
Adult  
Assumption: 
12-18 years 
1 – 2 tablets  
(500 mg – 1 g) 
4- 6 hourly 
(4 – 6 times) 
8 tablets in 
24 hours 
(4 g) 
Tablet 500 mg per 
tablet 
Children 
under 6 
Not 
recommended 
Not 
applicable 
Not 
applicable 
1. Panado tablets 
6 – 12 years ½ - 1 tablet 
(250 – 500 
mg) 
4 hourly Four doses 
for no longer 
than 5 days 
(2 g) 
12 – 18 
years 
Not listed Not 
applicable 
Not 
applicable 
Adult  
Assumption: 
12-18 years 
1 tablet, or 
1 – 2 tablets 
(500 mg – 1 g) 
3 hours, or 
4- 6 hourly 
4 g in 24 
hours 
Tablet  500 mg per 
tablet 
Not for 
children 
under 6 
years 
Not applicable Not 
applicable 
Not 
applicable 
1. Paracet Tablets 
6- 12 years ½ - 1 tablet 
(250 mg – 500 
mg) 
4 hourly 
(six times) 
Not listed 
Children over 
12 years 
1 – 2 tablets 
(500 mg – 1 g) 
4 hourly 
(six times) 
Not listed 
Tablet 500 mg per 
tablet 
Children 
under 6 
Not listed Not 
applicable 
Not 
applicable 
1. Prolief tablets 
6 – 12 years ½ - 1 tablet 
(250 – 500 
mg) 
4 hourly 
(six times) 
4 tablets in 
24 hours 
(2 g) 
Adults; 
assumption 
12 – 18 
years 
1 – 2 tablets 
(500 mg – 1 g) 
4 hourly 
(six times) 
8 tablets in 
24 hours 
(4 g) 
 
 
 
 
Form Strength – 
paracetamol 
per dosage 
unit 
Age Dosage 
(paracetamol 
quantity) 
Frequency Maximum daily 
dose 
Preparations 
Tablet 500 mg per 
tablet 
Children 
under six 
years 
Not listed Not 
applicable 
Not 
applicable 
1. Varipan tablets 
6- 12 years ½ - 1 tablet 
(250 – 500 
mg) 
6 - 8 hourly 4 tablets in 
24 hours 
(2 g) 
Adult 
assumption 
12 – 18years 
1 – 2 tablet 
(500 mg – 1 g) 
6 – 8 hourly 8 tablets in 
24 hours 
(4 g) 
Tablet 500 mg per 
tablet 
Not 
recommende
d for children 
under 12 
years 
Not applicable Not 
applicable 
Not 
applicable 
1. Grand-Pa 
Paracetamol 
tablets 
Adults 
assumption 
12 – 18 
years 
1 – 2 tablets 
(500 mg – 1 g) 
4- 6 hourly 4 g  
Difference - - - No maximum 1. Napamol tablets 
Difference 12 years and 
older 
1 tablet 
(500 mg) 
4 – 6 hourly 8 tablets in 
24 hours (4 
g) 
2. Painamol tablets 
Meltab 500 mg per 
tablet 
Adult  
Assumption: 
12-18 years 
1 – 2 tablets 
(500 mg – 1 g) 
4- 6 hourly 8 tablets in 
24 hours (4 
g) 
1. Panado Meltabs 
Efferve
scent 
tablet 
500 mg per 
tablet 
Not for 
children 
under 6 
years 
Not applicable Not 
applicable 
Not 
applicable 
1. Panado 
Effervescent 
tablet 
 6 – 12 years ½ - 1 tablet 
dissolved in 
water 
(250 – 500 
mg) 
Min interval 
is 4 hours 
Four doses 
in 24 hours 
(2 g) 
 Adult 
assumption 
12 - 18 years 
2 tablets 
dissolved in 
water 
(1 g) 
Four times 
daily 
Not listed 
 
 
 
 
Form Strength – 
paracetamol 
per dosage 
unit 
Age Dosage 
(paracetamol 
quantity) 
Frequency Maximum daily 
dose 
Preparations 
Capsul
es 
500 mg per 
capsule 
Not 
recommende
d for children 
under 9 
years 
Not applicable Not 
applicable 
Not 
applicable 
1. Panado 
Capsules 
9 – 12 years 1 capsule (500 
mg) 
Not specified 4 doses in 24 
hours 
(2 g) 
Adult: 
assumption 
12 – 18 
years 
1 – 2 capsules 
(500 mg – 1 g) 
4 hourly 8 capsules in 
24 hours  
(4 g) 
Meltab 125 mg per 
tablet 
1 – 5 years 1 – 2 tablets 
(125 mg – 250 
mg) 
4 hours Four doses 
in 24 hours 
maximum of 
5 days 
(1 g) 
1. Panado Children 
Meltabs 
Older than 5 
years 
Not listed Not 
applicable 
Not 
applicable 
 
RECTAL: N = 1 
Form Strength Age Dosage 
(paracetamol 
quantity) 
Frequency Maximum daily 
dose 
Preparations 
Sup
posit
ory 
125 mg or 
250 mg 
3 – 12 
months 
125 mg 3 - 4 times 
daily 
500 mg 1. Empaped 125 
mg and 250 mg 
(suppository) 
1- 5 years 250 mg 3- 4 times 
daily 
1 000 mg 
Alternate: 
10 mg/kg 
Not applicable 3 – 4 times 
daily 
Not listed 
If jaundices: 
5 mg/kg 
Not applicable 3 – 4 times 
daily 
Not listed 
 
 
 
 
 
 
INTRAVENOUS: N = 2 
Form Strength Age Dosage 
(paracetamol 
quantity) 
Frequency Maximum daily 
dose 
Preparations 
IV 
Solu
tion 
1 g per 100 
ml 
Children 
between 33 – 
50 kg 
15 mg/kg 
(1,5 ml/kg) 
over 15 
minutes 
4 times daily 
with min of 4 
hours 
between 
doses 
60 mg/kg not 
exceeding 4 
g 
1. Perfalgan 
Solution for 
infusion 
Adolescent 
over 50 kg 
1 g 4 times daily 
with min of 4 
hours 
between 
doses 
4 g 
IV 
Solu
tion 
10 mg per 
1 ml 
1 year and 
older with 
weight less 
than 33 kg 
(approximate
ly 11 years) 
15 mg/kg 4 times daily 
with min of 4 
hours 
between 
doses 
60 mg/kg 1. Perfalgan 
Paediatric 
Solution for 
infusion 
Children up 
to the age of 
years 
Not listed Not 
applicable 
Not 
applicable 
 
 
 
 
 
V1  
 28042014 
Summary of overdose information of paracetamol containing products 
South Africa 
 
Number Component in 
package insert 
MCC Package 
inserts for human 
use 
Product 
7 Yes Yes 1. Calpol Paediatric Syrup 
2. Grand-Pa Paracetamol tablets 
3. Panado Children meltabs 
4. Panado Meltabs 
5. Panado Paediatric Syrup 
6. Panado Paediatric Syrup 
Alcohol and sugar free 
7. Panado tablets 
13 Yes No 1. Adco Paracetamol Syrup 
2. Adco-Napamol Elixir 
3. Empaped 
4. Go-Pain Syrup 
5. Napamol Tablets 
6. Painamol Syrup 
7. Painamol Tablets 
8. Panado Capsules 
9. Panado Effervescent Tablets 
10. Panado Infants Drops 
11. Panado Paediatric Syrup 
Strawberry 
12. Perfalgan 
13. Perfalgan paediatric 
14. Woodward’s Paracetamol 
Syrup 
unknown Product labelling could not be 
obtained; MIMS information is 
abbreviated and summarised 
1. Austell Paracetamol 
2. Prolief Tablets 
3. Varipan tablets 
 No longer listed in MIMS (08/2013) 1. Antalgesic Syrup 
2. Antalgesic T Tablets 
3. Paracet tablets 
21 
evaluated 
 27 
 
 
 
 
 
1 of 2 Aadila Patel
Consolidation of responses from survey
PROFESSIONAL SURVEY: PARACETAMOL IN CHILDREN 12 YEARS AND UNDER
Respondent 1 2 3 4 5 No. Percentage
Response
1
Yes x x x x x 5 100
No n/a n/a n/a n/a n/a 0 0
2
Open question
2 yr / 6 yr 6 yr/ 12 yr 2 yr / 6 yr 0
1 tsp / not syrup 5 ml / 10 ml 5 ml / 10 ml 0
1/2 tablet child 
swallow
3
4 hours n/a n/a n/a n/a 0 0
6 hours x x x x 4 80
8 hours n/a n/a n/a n/a 0 0
1 20
4
Yes x x n/a x x 4 80
No n/a n/a x n/a n/a 1 20
5
Last month n/a x n/a n/a x 2 40
Last 3 months x n/a n/a n/a n/a 1 20
Last 12 months n/a n/a x x n/a 2 40
> 12 months ago
n/a n/a n/a n/a n/a 0 0
6
No x x n/a n/a x 3 60
Yes n/a n/a x x n/a 2 40
7
Yes x x x x n/a 4 80
No n/a n/a n/a n/a x 1 20
Syrup not 
effective for 6 yr 
for pain
As soon child 
swallow prefer 
solid dosage form
Baby hand 
out 
syringe 
always.
Prefer to 
give syrup.
Product as 
advertised 
on TV
Doctor 
tend 
prescribe 
4 to 6 
hourly
Do you PRESCRIBE paracetamol as first line treatment
What is the dose that you recommend
What is the frequency of the dose
Do you look at the package insert of the product that 
When last have you looked at the package insert
Do you hand out a medicine measure
Do you ask if the caregiver has an adequate dispensing 
device (medicine measure) to dose  the child
Comments shared
As per 
package 
insert
As per 
package 
insert
As 
prescribed 
by doctor 
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Not effective for 
migraine
devices 
need to 
procured 
as a 
separate 
item
Sometime
s ask 
about 
device and 
hands out
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Respondent 1 2 3 4 5 6 7 8 9 10 No. Percentage
Response
1
Pain x x x x x x x x x x 10 100
Fever x x x x x x x x x x 10 100
Other n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 0
2
Yes x x x x x x x x x x 10 100
No n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0
3
Open question 4 yr / 10 yr All ages 2 year 2 year All ages 2 year 6 yr / 8 yr 3, 5 years 2 year 5 yr /10 yr
1 tsp / 2 
tsp
As per 
directions
Pharma-
cist 
recommend
ation
1 tsp 5 ml 5 ml 7,5 ml / 10 
ml
1 tsp 5 ml 1 tsp / 10 
ml
4
4 hours x n/a n/a n/a n/a n/a n/a x x n/a 3 30
6 hours n/a x x n/a x n/a x n/a n/a n/a 4 40
8 hours n/a n/a n/a x n/a x n/a n/a n/a x 3 30
5
Yes x x x x n/a n/a x x x x 8 80
No n/a n/a n/a n/a x x n/a n/a n/a n/a 2 20
6
Last month n/a x x x n/a n/a x x x x 7 70
Last 3 months n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 0
Last 12 months x n/a n/a n/a n/a n/a n/a n/a n/a n/a 1 10
> 12 months ago n/a n/a n/a n/a x x n/a n/a n/a n/a 2 20
When last have you looked at the package insert
Do you look at the package insert of the product before giving the paracetamol syrup
CAREGIVER SURVEY: PARACETAMOL IN CHILDREN 12 YEARS AND UNDER
Why do you give your child (or child under your care) paracetamol?
Do you use paracetamol as first line of treatment
What is the dose that you give to the child
How often do you give the child paracetamol
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7
Teaspoon x n/a n/a x n/a x n/a x x x 6 60
Tablespoon n/a x n/a n/a x n/a x n/a n/a n/a 3 30
Medicine measure n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 0
Syringe n/a n/a x n/a n/a n/a n/a n/a n/a n/a 1 10
8
Yes n/a x n/a x x n/a n/a n/a n/a n/a 3 30
No n/a n/a x n/a n/a x x x x x 6 60
1 10
9
3 - 5 days x x x x x x x x x 9 90
10 days n/a n/a n/a n/a n/a n/a n/a n/a n/a 0 0
Other n/a After 24 hrs n/a n/a n/a n/a n/a n/a n/a n/a 1 10
works all 
the time
Grow up 
with 
originator
works all 
the time
Abbreviations:
tsp : teaspoon
yr: year
hrs: hours
How do you give the child paracetamol
Do you tell the pharmacist or doctor if you think that the product is not working
For how long do you use paracetamol before you go to seek the advice of your pharmacist or 
Comments shared
 
 
 
 
